US20190010149A1 - Sustained-release formulation for injection - Google Patents
Sustained-release formulation for injection Download PDFInfo
- Publication number
- US20190010149A1 US20190010149A1 US16/128,597 US201816128597A US2019010149A1 US 20190010149 A1 US20190010149 A1 US 20190010149A1 US 201816128597 A US201816128597 A US 201816128597A US 2019010149 A1 US2019010149 A1 US 2019010149A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- active ingredient
- solution
- crystal
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 367
- 238000009472 formulation Methods 0.000 title claims abstract description 292
- 238000013268 sustained release Methods 0.000 title claims abstract description 77
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 77
- 238000002347 injection Methods 0.000 title abstract description 75
- 239000007924 injection Substances 0.000 title abstract description 75
- HUXSAESWQBPYHL-UHFFFAOYSA-N azecane-2,10-dione Chemical compound O=C1CCCCCCCC(=O)N1 HUXSAESWQBPYHL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims description 205
- 239000013078 crystal Substances 0.000 claims description 197
- 239000002245 particle Substances 0.000 claims description 148
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 105
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 60
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 60
- 229920000053 polysorbate 80 Polymers 0.000 claims description 60
- 229940068968 polysorbate 80 Drugs 0.000 claims description 60
- 239000004094 surface-active agent Substances 0.000 claims description 53
- 239000000872 buffer Substances 0.000 claims description 46
- 239000004615 ingredient Substances 0.000 claims description 45
- -1 polyoxyethylene Polymers 0.000 claims description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 36
- 239000004359 castor oil Substances 0.000 claims description 36
- 235000019438 castor oil Nutrition 0.000 claims description 36
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 36
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 31
- 239000007951 isotonicity adjuster Substances 0.000 claims description 27
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 17
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 17
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 17
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 15
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 15
- 229940068977 polysorbate 20 Drugs 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 14
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 12
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 12
- 229960003194 meglumine Drugs 0.000 claims description 12
- 229920001993 poloxamer 188 Polymers 0.000 claims description 12
- 229940044519 poloxamer 188 Drugs 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 10
- 229960000281 trometamol Drugs 0.000 claims description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- 208000020016 psychiatric disease Diseases 0.000 claims description 8
- 201000000980 schizophrenia Diseases 0.000 claims description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 7
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 7
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 235000011008 sodium phosphates Nutrition 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 4
- 235000011009 potassium phosphates Nutrition 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 29
- 150000003839 salts Chemical class 0.000 abstract description 12
- 239000002253 acid Substances 0.000 abstract description 11
- 230000036765 blood level Effects 0.000 abstract description 11
- 239000000243 solution Substances 0.000 description 258
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 86
- 239000003981 vehicle Substances 0.000 description 86
- 239000003795 chemical substances by application Substances 0.000 description 79
- 238000003756 stirring Methods 0.000 description 74
- 230000008569 process Effects 0.000 description 60
- 238000009826 distribution Methods 0.000 description 54
- 229940125904 compound 1 Drugs 0.000 description 42
- 239000002002 slurry Substances 0.000 description 42
- 239000000725 suspension Substances 0.000 description 37
- 239000011521 glass Substances 0.000 description 36
- 230000037361 pathway Effects 0.000 description 34
- 239000003960 organic solvent Substances 0.000 description 33
- 239000011148 porous material Substances 0.000 description 33
- 238000002425 crystallisation Methods 0.000 description 31
- 230000008025 crystallization Effects 0.000 description 31
- 150000008064 anhydrides Chemical class 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- 230000001954 sterilising effect Effects 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000004659 sterilization and disinfection Methods 0.000 description 20
- 239000008215 water for injection Substances 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 17
- 239000000463 material Substances 0.000 description 16
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 150000004683 dihydrates Chemical class 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000004809 Teflon Substances 0.000 description 11
- 229920006362 Teflon® Polymers 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940071643 prefilled syringe Drugs 0.000 description 10
- 239000008174 sterile solution Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 229950008882 polysorbate Drugs 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 238000002525 ultrasonication Methods 0.000 description 9
- 238000000634 powder X-ray diffraction Methods 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- 229940102213 injectable suspension Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000013022 formulation composition Substances 0.000 description 6
- 229960004592 isopropanol Drugs 0.000 description 6
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical group NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 5
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 description 5
- 229940001593 sodium carbonate Drugs 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 229960004418 trolamine Drugs 0.000 description 5
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960001716 benzalkonium Drugs 0.000 description 4
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000015277 pork Nutrition 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000010025 steaming Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 229920000591 gum Polymers 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229940025708 injectable product Drugs 0.000 description 3
- 229950007594 meprylcaine Drugs 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229960001309 procaine hydrochloride Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 229960004372 aripiprazole Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960002160 maltose Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000090599 Plantago psyllium Species 0.000 description 1
- 235000010451 Plantago psyllium Nutrition 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ITLVJEYRPIYSOW-UHFFFAOYSA-N [K].[K].[K] Chemical compound [K].[K].[K] ITLVJEYRPIYSOW-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920001973 fluoroelastomer Polymers 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 238000010058 rubber compounding Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl] (1′R,2′S, 3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof (hereinafter, optionally referred to as “the present compound”).
- the present invention relates to a sterile suspension formulation which can maintain an effective blood level of the present compound as a sustained release formulation for injection.
- the present invention relates to a process of the formulation comprising the present compound.
- Compound 1 N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl] (1′R,2′S,3′R, 4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide hydrochloride (hereinafter, optionally referred to as “Compound 1”) has psychotropic activity and is useful as a therapeutic agent for diseases such as schizophrenia.
- Patent Reference 1 describes that Compound 1 is usually administered orally.
- a depot formulation for intramuscular injection comprising an injectable suspension of a medicament is generally known as one of administration means for sustained-release of a medicament.
- An injectable suspension is in a heterogeneous system comprising a solid phase dispersed in an aqueous or nonaqueous liquid phase, which requires sterile, stable, resuspendable, syringeable, injectable, isotonic, and nonirritating.
- Patent Reference 2 discloses a composition comprising microparticles comprising a polymeric binder, and an aqueous injectable vehicle.
- the composition has a constructional property wherein the microparticles have a mass median diameter of at least about 10 ⁇ m, and the vehicle comprises a viscosity enhancing agent.
- a formulation comprising aripiprazole makes such requirements satisfied by reducing the mean particle size of the compound and adding a specific suspending agent such as carboxymethylcellulose thereto (Patent Reference 3).
- a formulation comprising olanzapine makes such requirements satisfied by further reducing the size of the compound to nanoparticles and using a surface stabilizer such as polysorbate (Patent Reference 4).
- a surface stabilizer such as polysorbate
- a process under aseptic atmosphere is generally accompanied with some complicated and troublesome steps and manufacturing-operations.
- some strict controls such as sterilization of apparatuses and devices, education and training for operators, and control of the number of environmental microbials and microparticles in an aseptic plant are also required.
- Patent Reference 1 JP Patent No. 2800953
- Compound 1 has a low solubility in water, and exhibits poor water solubility and hydrophobicity. This means that it is technically difficult to formulate the compound as an injectable product.
- Compound 1 when Compound 1 is dispersed in water, the particles thereof tend to come up to the surface or adhere to the container wall, and thus it was difficult to satisfy the suspensibility as an injectable suspension product.
- Patent Reference 4 teaches that the releasing time can be adjusted by optimally controlling the particle size and it is preferred to keep the mean particle size of an active ingredient as small as possible.
- Compound 1 when the mean particle size thereof was too small, the sustained release for a long period could not be attained; whereas when the particles of bigger mean particle size were used so that the sustained release for a long period could be attained, then an injection needle was clogged with the particles, thus it was found that such bigger particles was difficult for be injected.
- a problem to be solved by the invention is to provide a formulation that can maintain an effective blood level of the present compound for a long period (hereinafter, optionally referred to as “the present formulation”).
- the invention is intended to provide a process to accurately control the particle size of the present compound (hereinafter, optionally referred to as “the present process”).
- the invention is intended to provide a sterile and dust-free suspension formulation which can be easily processed without using complicated dosage forms and/or complicated processes.
- the present inventors have extensively studied to reach the above object and have surprisingly found that the above-mentioned problems could be solved by using a specific mean particle size of the present compound, a specific nonionic surfactant, and an active ingredient having an optimized concentration.
- the prepared suspension formulation for injection thereby exhibits a good suspensibility and is able to pass through an injection needle easily. Based upon the new findings, the present invention has been completed.
- the present inventions are as follows:
- composition comprising the following (1) to (5),
- a surfactant comprising at least one ingredient selected from the group consisting of polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188 and polyoxyethylene castor oil,
- a buffer comprising at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid,
- an isotonic agent comprising at least one ingredient selected from the group consisting of sodium chloride and D-mannitol, and
- composition of Term 1 wherein the active ingredient is in a crystal form.
- composition of Term 2 wherein the mean particle size of the crystal is about 4 ⁇ m-about 55 ⁇ m, about 4 ⁇ m-about 26 ⁇ m, about 4 ⁇ m-about 20 ⁇ m, about 4 ⁇ m-about 18 ⁇ m, about 4 ⁇ m-about 16 ⁇ m, about 5 ⁇ m-about 55 ⁇ m, about 5 ⁇ m-about 26 ⁇ m, about 5 ⁇ m-about 20 ⁇ m, about 5 ⁇ m-about 18 ⁇ m, about 5 ⁇ m-about 16 ⁇ m, about 8 ⁇ m-about 55 ⁇ m, about 8 ⁇ m-about 20 ⁇ m, about 10 ⁇ m-about 55 ⁇ m, about 10 ⁇ m-about 26 ⁇ m, about 10 ⁇ m-about 20 ⁇ m, about 10 ⁇ m-about 18 ⁇ m, or about 10 ⁇ m-about 16 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 5 ⁇ m-about 55 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 5 ⁇ m-about 26 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 5 ⁇ m-about 20 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 5 ⁇ m-about 16 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 10 ⁇ m-about 20 ⁇ m.
- composition of Term 3 wherein the mean particle size of the crystal is about 10 ⁇ m-about 16 ⁇ m.
- composition of any one of Terms 2 to 9 wherein the crystal is a cubic crystal.
- composition of Term 10 wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2.
- composition of any one of Term 2 to 11 wherein the active ingredient in crystal form is contained in about 5% (w/v) to about 60% (w/v) per the whole of the composition.
- composition of any one of Terms 1 to 12 wherein the surfactant is polysorbate 80.
- composition of any one of Terms 1 to 14 wherein the buffer is at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid.
- composition of Term 15 wherein the buffer is sodium dihydrogenphosphate and/or disodium hydrogenphosphate.
- composition of any one of Terms 1 to 17 wherein the isotonic agent is sodium chloride.
- a sustained release formulation for injection which comprises the composition according to any one of Terms 1 to 19.
- Term 20 wherein the active ingredient is contained in a concentration of about 50 mg/mL to about 600 mg/mL.
- Term 21 wherein the active ingredient is contained in a concentration of about 50 mg/mL to about 400 mg/mL.
- Term 22 wherein the active ingredient is contained in a concentration of about 100 mg/mL to about 400 mg/mL.
- Term 23 wherein the active ingredient is contained in a concentration of about 100 mg/mL to about 200 mg/mL.
- Term 23 wherein the active ingredient is contained in a concentration of about 200 mg/mL to about 400 mg/mL.
- Term 29 which contains about 100 mg to about 800 mg of the active ingredient per a container.
- a process of a sustained-release sterile formulation for injection comprising the following steps (1) to (5):
- step (1) dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water, and then sterilely-filtering the solution,
- step (2) preparing a water solution comprising a surfactant and a buffer, sterilely filtering the water solution, and then sterilely putting the water solution into a sealed vessel whose inside is sterilized,
- step (3) sterilely adding the sterile solution prepared in step (1) into the sealed vessel containing the water solution prepared in step (2),
- step (4) collecting a crystal precipitated in step (3) through a filter in the sealed vessel, and
- step (5) preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection, sterilely filtering the water solution, and then sterilely putting the water solution into the sealed vessel containing the crystal in step (4) and mixing the water solution and the crystal.
- a process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1) dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2) preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent),
- step (3) adding the solution of the active ingredient prepared in step (1) into the crystallizing agent in step (2),
- step (4) collecting a crystal precipitated in step (3) through a filter
- step (5) preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then mixing the water solution and the crystal of the active ingredient prepared in step (4) to prepare a suspension formulation.
- a process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1) dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2) preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent), and then injecting the water solution into a vessel for crystallization,
- a buffer i.e. a crystallizing agent
- step (3) adding the solution of the active ingredient prepared in step (1) into the vessel for crystallization containing the crystallizing agent in step (2),
- step (4) collecting a crystal precipitated in step (3) through a filter in the vessel for crystallization, and
- step (5) preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then injecting the water solution into the crystal of the active ingredient prepared in step (4) and mixing the water solution and the crystal to prepare a suspension formulation.
- step (6) aseptically filling a formulation container with the suspension formulation prepared in step (5) to prepare a filled suspension formulation
- step (7) sterilizing the filled suspension formulation prepared in step (6) by a process of steaming under pressure
- step (8) ultrasonicating the filled suspension formulation prepared in step (7).
- step (3) the solution of the active ingredient is added to the crystallizing agent in the vessel for crystallization (or the sealed vessel) while circulating the solution (or the suspension solution) in the vessel for crystallization (or the sealed vessel) via a bypass pathway equipped with a pump which can pressure a solution.
- a roller pump tube pump, hose pump
- a reciprocating pump piston pump, plunger pump, diaphragm pump
- a rotary pump gear pump, vane pump, screw pump
- a process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1) dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2) preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent) and injecting the water solution into a vessel for crystallization equipped with a stirring system,
- a buffer i.e. a crystallizing agent
- step (3) adding the solution of the active ingredient to the crystallizing agent in the vessel for crystallization while circulating the solution (or the suspension solution) in the vessel for crystallization via a bypass pathway equipped with a pump which (i) is connected to the vessel for crystallization, (ii) can make the solution in the vessel for crystallization circulated, and (iii) can pressure the solution,
- step (4) collecting a crystal precipitated in the vessel for crystallization from the solution (or the suspension solution) in step (3) through a filter, and
- step (5) preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then injecting the water solution into the crystal of the active ingredient prepared in step (4) and mixing them to prepare a suspension formulation.
- a process of a sustained-release formulation for injection comprising the following steps (4) to (8):
- step (4) preparing a vehicle solution comprising a surfactant, a buffer, an isotonic agent and water for injection,
- step (5) injecting the vehicle solution in step (4) into a crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide and mixing them to prepare a suspension formulation,
- step (6) aseptically filling a formulation container with the suspension formulation prepared in step (5) to prepare a filled suspension formulation
- step (7) sterilizing the filled suspension formulation prepared in step (6) by a process of steaming under pressure
- step (8) ultrasonicating the filled suspension formulation prepared in step (7).
- each the surfactant is independently at least one ingredient selected from the group consisting of polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride and sodium lauryl sulfate.
- organic solvent is at least one solvent selected from the group consisting of 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide and N,N-dimethylacetamide.
- Term 48 The process of any one of Terms 33 to 47 wherein the solvent used in step (1) is a mixture of an organic solvent and water.
- each the buffer is independently at least one ingredient selected from the group consisting of sodium dihydrogenphosphate, disodium hydrogenphosphate, potassium dihydrogenphosphate, dipotassium hydrogenphosphate, sodium carbonate, triethanolamine, arginine and meglumine.
- a sustained release formulation for injection which is prepared through the process of any one of Terms 33 to 54.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 5 ⁇ m-about 55 ⁇ m.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 5 ⁇ m-about 26 ⁇ m.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 5 ⁇ m-about 20 ⁇ m.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 5 ⁇ m-about 16 ⁇ m.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 10 ⁇ m-about 20 ⁇ m.
- the crystal of Term 56 wherein the mean particle size of the crystal is about 10 ⁇ m-about 16 ⁇ m.
- the crystal of Term 66 which is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:0.8 to about 1:1.2, and the ratio between length and height thereof is about 1:0.1 to about 1:3.
- a depot formulation for injection comprising the crystal of any one of Terms 56 to 67.
- the depot formulation for injection of Term 68 wherein the crystal is suspended in a medium of the formulation.
- the depot formulation for injection of any one of Terms 68 to 70 which further comprises a surfactant, a buffer and an isotonic agent.
- a package containing a container which contains the sustained release formulation for injection comprising the crystal of any one of Terms 56 to 67.
- a method for treating psychiatric disease which comprises administering the formulation of any one of Terms 20 to 32, 55, and 68 to 71.
- Term 73 The method of Term 73 wherein the psychiatric disease is schizophrenia.
- psychiatric disease is bipolar disorder.
- Term 73 wherein the psychiatric disease is depression.
- the present formulation can maintain an effective blood level of the present compound for at least 2 to 4 weeks or more by intramuscular administration. Consequently, using the present formulation, it is possible to decrease the frequency of administration compared with an oral formulation containing the present compound.
- the present formulation is injectable (i.e. has a good needle passability) even though the present compound is suspended in the present formulation.
- the present process provides the formulation to maintain an effective blood level of the present compound for at least 2 to 4 weeks or more by suspending the present compound in the formulation.
- the present process is useful in the point that the preparation is carried out under a sequential sterile and/or dust-free processing, further via a continuous formulating process.
- FIG. 1 shows a photomicrograph of the crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide.
- FIG. 2 is a graph showing a transition of the average concentration of drug in the plasma when the formulation prepared in Example 12 (200 mg/mL) was administered to rats in a dose of 50 mg/kg.
- FIG. 3 is a graph showing a transition of the average concentration of drug in the plasma when the formulation prepared in Example 13 (400 mg/mL) was administered to rats in a dose of 100 mg/kg.
- FIG. 4 is a photograph showing that the non-ultrasonicated formulation prepared in Example A2 contains macroaggregated particles.
- FIG. 5 is a photograph showing that the ultrasonicated formulation (35 kHz, 3 min) prepared in Example A2 contains no macroaggregated particles.
- FIG. 6 is an X-ray diffraction in the sample before the steam sterilization under pressure in Example A3.
- FIG. 7 is an X-ray diffraction in the sample after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min) in Example A3.
- active ingredient used herein is N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof.
- the term refers to N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a hydrochloride thereof.
- concentration of the active ingredient used herein is within about 5% (w/v) to about 60% (w/v) per the whole of the formulation as a free form.
- the concentration of the active ingredient in the formulation is preferably about 50 mg/mL to about 600 mg/mL as a free form, and more preferably about 50 mg/mL to about 400 mg/mL, about 100 mg/mL to about 400 mg/mL, about 100 mg/mL to about 200 mg/mL, or about 200 mg/mL to about 400 mg/mL as a free form.
- the “particle size” is controlled to maintain an effective blood level of the active ingredient for at least two weeks, preferably for at least four weeks.
- the mean particle size of the “active ingredient” used herein is in a range selected from the group consisting of about 4 ⁇ m-about 55 ⁇ m, about 4 ⁇ m-about 26 ⁇ m, about 4 ⁇ m-about 20 ⁇ m, about 4 ⁇ m-about 18 ⁇ m, about 4 ⁇ m-about 16 ⁇ m, about 5 ⁇ m-about 55 ⁇ m, about 5 ⁇ m-about 26 ⁇ m, about 5 ⁇ m-about 20 ⁇ m, about 5 ⁇ m-about 18 ⁇ m, about 5 ⁇ m-about 16 ⁇ m, about 8 ⁇ m-about 55 ⁇ m, about 8 ⁇ m-about 20 ⁇ m, about 10 ⁇ m-about 55 ⁇ m, about 10 ⁇ m-about 26 ⁇ m, about 10 ⁇ m-about 20 ⁇ m, about 10 ⁇ m-about 18 ⁇ m, and about 10
- the mean particle size is about 5 ⁇ m-about 55 ⁇ m, about 5 ⁇ m-about 26 ⁇ m, about 5 ⁇ m-about 20 ⁇ m, about 5 ⁇ m-about 16 ⁇ m, about 10 ⁇ m-about 20 ⁇ m, or about 10 ⁇ m-about 16 ⁇ m.
- mean particle size also referred to as D50
- D50 mean particle size
- the term “pharmaceutically acceptable acid addition salt” used herein is defined as an addition salt with an inorganic acid or an organic acid.
- the inorganic acid includes, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid.
- the organic acid includes, for example, phosphoric acid, acetic acid, oxalic acid, citric acid, malic acid, tartaric acid, maleic acid, and fumaric acid.
- the salt is hydrochloride.
- the “surfactant” is used to improve the suspensibility of the crystal in the present formulation, and is contained in a range of about 0.005 to about 2% (w/v) per the whole of the formulation, preferably about 0.01 to about 1% (w/v). In addition, the surfactant is contained in a concentration of about 0.05 mg/mL to about 20 mg/mL.
- the surfactant includes, for example, polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, and polyoxyethylene castor oil.
- the surfactant is polysorbate 80.
- the present invention may contain more than two surfactants.
- the “buffer” is used in an appropriate amount to adjust the pH of the aqueous suspension in the present formulation to an injectable range, for example about pH 6 to about pH 8 and preferably about pH 7.
- the buffer is contained in a range of about 0.01 to about 2% (w/v) per the whole of the formulation, and preferably about 0.05 to about 1% (w/v).
- the buffer is contained in a concentration of about 0.1 mg/mL to about 20 mg/mL.
- the buffer includes, for example, sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine, and citric acid.
- the buffer is sodium phosphate.
- the present invention may contain more than two buffers.
- the “isotonic agent” is used to adjust the osmotic pressure of the present formulation to an injectable range.
- the isotonic agent is contained in a range of about 0.1 to 10% (w/v) per the whole of the formulation, preferably about 0.2 to about 5% (w/v).
- the isotonic agent is contained in a concentration of about 1 mg/mL to about 100 mg/mL.
- the isotonic agent includes, for example, sodium chloride, and D-mannitol.
- the isotonic agent is sodium chloride.
- water used herein is defined as purified water, or the same or a higher grade thereof; and such water needs to be sterilized after dissolving various ingredients therein, or already-sterilized water (e.g. water for injection) is used in the process which is carried out under sterile condition throughout the steps.
- water for injection used herein includes water sterilized through a sterile filter etc. after dissolving substrates or reagents into the above-mentioned “water” (as a starting material).
- the crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof is characterized by a cubic crystal form just after being prepared through the present process. And then, the crystal might be gradually rounded and transformed into a spherical form during storage.
- the cubic crystal used herein includes not only perfect cubic shapes but also cuboidal shapes (e.g. shapes whose ratio between length and width is about 1:0.8 to about 1:1.2, and the ratio between length and height thereof is about 1:0.1 to about 1:3, etc.).
- the “sustained release formulation for injection” used herein means a formulation which can maintain the blood level of the active ingredient for at least two to four weeks after intramuscular injection.
- the present formulation may contain other additive agents unless there are any adverse effects on the present invention.
- the other additive agents includes, for example, pH regulators such as hydrochloric acid, acetic acid, lactic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, and sodium hydroxide; soothing agents such as lidocaine hydrochloride, meprylcaine hydrochloride and procaine hydrochloride; water-soluble polymers such as carboxymethylcellulose sodium, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol 4000, carboxy vinyl polymer, polypeptide, polyamino acid, dextrin, gum arabic, sodium alginate, pullulan, sodium hyaluronate, sodium chondroitin sulfate, gelatin, collagen, agarose, xanthane gum, gellan gum, tamarind gum, guar
- the present formulation can be administered parenterally, in particular, intramuscularly or subcutaneously as a sustained release formulation for injection, at a dose of 50 to 1200 mg (preferably 100 to 800 mg) of the active ingredient.
- the present formulation can be administered once in two to six weeks, preferably once in four to six weeks, and more preferably once in four weeks.
- the present formulation may contain 50 to 1200 mg of the active ingredient per a bottle, and preferably 100 to 800 mg thereof.
- the present formulation can be administered intramuscularly or subcutaneously with a prefilled syringe equipped with a needle which is filled with the present formulation.
- the present formulation can be administered through the following steps; i.e., from a vial filled with the present formulation, the content is transferred into an injection syringe via a needle and then administered intramuscularly or subcutaneously.
- the present formulation may be put into a container such as a vial and then lyophilized to give a lyophilize formulation, or the crystal of the active ingredient in the present formulation may be isolated, dried, and then put into a container such as a vial to give a powder-filled formulation.
- the lyophilize formulation or the powder-filled formulation can be administered intramuscularly or subcutaneously as an injectable suspension which is prepared by putting a suspending solution into the container via a needle just before use.
- a needle of 18 gauge (internal diameter thereof: 0.90 mm) to 23 gauge (internal diameter thereof: 0.33 mm) may be used for the intramuscular or subcutaneous administration.
- the container filled with the formulation of the present invention can be set in a needleless syringe which can administer a drug solution in the container by discharging the solution with a pressure prepared by a gas, a detonator, a spring, etc. packed in the syringe device without using any needle to administer the drug solution intramuscularly or subcutaneously.
- the formulation of the present invention includes a form of liquid such as a suspension which can be put in a formulation container, a form wherein the liquid such as a suspension is already put in a formulation container, and further a form wherein the formulation container containing the liquid is sterilized and/or ultrasonicated.
- the present formulation can be prepared according to, for example, the following steps, but are not limited thereto.
- the present compound is dissolved in water, an organic solvent or a mixture thereof with a surfactant to prepare a solution of the active ingredient.
- the resulting solution is sterilely filtered through a sterile filter to prepare a sterile solution of the active ingredient.
- the solvent used herein water, an organic solvent or a mixture thereof
- the solvent used herein is preferably an organic solvent or a mixture of an organic solvent and water, more preferably a mixture of an organic solvent and water.
- Sterile filters are effective not only for sterilely-filtering, but also for removing foreign substances derived from starting materials or foreign substances immixed as a contamination during processing steps.
- the surfactant includes, for example, polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride, and sodium lauryl sulfate.
- two or more of the surfactants may be used.
- the surfactant is polysorbate 80.
- the surfactant is contained in about 0.005% (w/v) to about 10% (w/v).
- the water used herein is purified water or the same or high level of water, or water for injection.
- the organic solvent includes, for example, alcohol solvents (e.g. methanol, ethanol, etc.), and aprotic solvents (e.g. acetone, dimethylsulfoxide, N,N-dimethylacetamide, etc.). In addition, two or more of the solvents may be used.
- the organic solvent is 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide, or N,N-dimethylacetamide.
- mixture of an organic solvent and water is defined as a mixed solvent comprising the above-mentioned alcohol solvent and/or the above-mentioned aprotic solvent and water (hereinafter, the mixture of an alcohol solvent and water is optionally referred to as “water-containing alcohol solvent”).
- the mixture of an organic solvent and water includes, for example, a mixture of 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide, or N,N-dimethylacetamide, and water.
- the preferable mixture is a mixture of ethanol and water (optionally referred to as “water-containing ethanol”).
- the organic solvent in the mixture of an organic solvent and water may be contained in the range of 0% to 100% as long as the organic solvent and water can be homogeneously mixed, for example, in 30% to 95%, preferably 40% to 90%, more preferably 50% to 90%, and even more preferably 60% to 80%. It is especially preferred that the mixture is 70% water-containing ethanol. Preferably, the organic solvent is contained in about 50 to about 90% per the whole volume of the composition.
- the temperature in this step is about 1 to about 90° C., preferably about 5 to about 60° C.
- a water solution comprising a surfactant and a buffer is prepared to give a crystallizing agent.
- the water solution (crystallizing agent) is sterilely filtered through a sterile filter to give a sterile crystallizing agent, and then the agent is sterilely put into a vessel for crystallization whose inside is sterilized (hereinafter, optionally referred to as a “sealed-type vessel for crystalline” or a “sealed vessel”).
- the surfactant includes, for example, polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride, and sodium lauryl sulfate. Two or more of the surfactants may be used.
- the surfactant may be added to the water solution (i.e. crystallizing agent) and/or the sterile solution prepared in step (1) (i.e. sterile solution of the active ingredient).
- the surfactant is polysorbate 80.
- the surfactant is contained in about 0.005% (w/v) to about 10% (w/v).
- the buffer includes, for example, sodium phosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate, potassium dihydrogenphosphate, dipotassium hydrogenphosphate, sodium carbonate, triethanolamine, arginine, and meglumine. Two or more of the buffers may be used.
- the buffer is sodium dihydrogenphosphate or disodium hydrogenphosphate.
- the buffer is contained in about 0.01% (w/v) to about 8% (w/v).
- the pH of the water solution is about 5 to about 12, and preferably about 7 to about 10.
- the temperature in this step is about 1 to about 90° C., and preferably about 5 to about 80° C.
- the sealed vessel used in this step includes, for example, a vessel made of stainless (e.g. SUS304, SUS316, SUS316L) which is equipped with pipe arrangement, ferrule, valve, jacket, air filter, stirring system, etc.
- the stirring system includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings), a homomixer, a static mixer and a stirring bar for a magnetic stirrer.
- the sterile solution prepared in step (1) (sterile solution of the active ingredient) is sterilely dropped into the vessel for crystallization (sealed vessel) containing the water solution prepared in step (2) (crystallizing agent).
- the volume ratio between the solutions of step (2) and step (1) i.e. volume ratio between the crystallizing agent and the solution of the active ingredient is about 1:0.1 to about 1:10, preferably about 1:0.2 to about 1:2.
- the present compound is crystallized in this step.
- the precipitated crystal is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2.
- the mean particle size of the crystal can be controlled by adjusting the crystallizing temperature, stirring speed, dropping rate, etc., or by adjusting the circulation velocity when using a bypass pathway mentioned below.
- the crystallizing temperature is preferably about 1 to about 90° C., and more preferably about 5 to about 60° C.
- the stirring speed is preferably about 50 rpm to about 10000 rpm, more preferably 100 rpm to about 5000 rpm, even more preferably about 100 rpm to about 2000 rpm, and the most preferably about 300 rpm to about 1500 rpm.
- the dropping rate is calculated by dividing the total volume of the sterile solution of step (1) (i.e. sterile solution of the active ingredient) to be added in Step (3) by the desired time. The dropping rate is, when the total dropped volume of the solution of the active ingredient is n L, preferably about n ⁇ 0.01 L/min.
- the dropping rate is about 0.01 L/min to 1 L/min, preferably about 0.01 L/min to about 0.2 L/min, more preferably about 0.05 L/min to about 0.2 L/min; and when the total dropped volume of the solution of the active ingredient is 100 L, the dropping rate is about 1 L/min to 100 L/min, preferably about 1 L/min to about 20 L/min, more preferably about 5 L/min to about 20 L/min.
- the dropping rate is about 10 L/min to 1000 L/min, preferably about 10 L/min to about 200 L/min, more preferably about 50 L/min to about 200 L/min.
- the sterile solution (sterile solution of the active ingredient) prepared in step (1) can be sterilely added dropwise thereto and simultaneously circulating the solution in the vessel for crystallization via a sealed bypass pathway.
- the bypass pathway has a pump which can pressure a solution in the pathway.
- pump which can pressure a solution includes, for example, a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump), preferably a roller pump.
- the circulation velocity in the bypass pathway is preferably about n ⁇ 0.001 L/min to about n ⁇ 2 L/min, more preferably about n ⁇ 0.01 L/min to about n ⁇ 1 L/min wherein “n” denotes the total volume of the crystallizing agent and the solution of the active ingredient.
- the circulation velocity is about 1 mL/min to about 2000 mL/min, preferably about 10 mL/min to about 1000 mL/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1 L; about 100 mL/min to about 200 L/min, preferably about 1 L/min to about 100 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 100 L; and about 1 L/min to about 2000 L/min, preferably about 10 L/min to about 1000 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1000 L.
- the crystal precipitated in step (3) is collected through a filter in the sealed vessel.
- the crystal produced under the condition of in step (3) such as crystallizing temperature and stirring speed has uniform mean particle sizes.
- the method therefore can prepare a crystal having uniform mean particle sizes without any milling steps.
- the sealed vessel used in this step includes, for example, a pressurized vessel made of stainless (e.g. SUS304, SUS316, SUS316L) which is equipped with pipe arrangement, ferrule, valve, crystal collection filter, jacket, air filter, stirring system, etc.
- the stirring system includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings) and a stirring bar for a magnetic stirrer.
- a water solution comprising a surfactant (about 0.005 to about 2% (w/v) per the whole of the final formulation), a buffer (about 0.01 to about 2% (w/v) per the whole of the final formulation), an isotonic agent (about 0.1 to about 10% (w/v) per the whole of the final formulation), and water for injection is prepared.
- the vehicle solution may further comprise a pH regulator, a soothing agent, a polymer, etc.
- the prepared solution is sterilely filtered through a sterile filter.
- the resulting vehicle solution is sterilely put into the sealed vessel of step (4) to wash the crystal in the vessel. The washing process may be repeated several times.
- the vehicle solution can be sterilely put into the sealed vessel again and mixed with the crystal to provide a suspension formulation which is the formulation of the invention.
- the sterile active ingredient prepared in step (4) may be continuously suspended in the vehicle solution to provide an injectable product (suspension formulation), and furthermore, the active ingredient obtained from the crystallization may be washed with water, an organic solvent or a mixture thereof any of which are sterilely filtered through a sterile filter, and then dried for a while and suspended in the vehicle solution again to prepare a suspension formulation.
- the suspension formulation prepared in Step (5) can be formed as a prefilled formulation through the following step (6).
- the suspension formulation prepared in Step (5) is sterilely put into a container for formulation such as a prefilled syringe, a vial, an ampule, a bag or a Blow-Fill-Seal container.
- the preferred container includes a prefilled syringe and a vial.
- Steps (1) to (6) in the Preparation Method A mentioned above can be continuously carried out under sterile conditions without taking out the crystal during the process.
- the present process it is possible to easily prepare a sustained release formulation for injection without using the steps of gas sterilization, gamma-ray sterilization, or electron beam sterilization, which is a sterile and dust-free formulation.
- the present process provides a sustained-release sterile formulation for injection wherein the active ingredient is uniformly suspended in the solvent.
- Preparation Method A can be partially modified as follows.
- the suspension formulation prepared via Step (1) to Step (5) or Step (6) is not necessarily ensured about sterility.
- the embodiments or preferable embodiments of a surfactant, water, an organic solvent, a mixed solvent of an organic solvent and water, a buffer, an isotonic agent, a bypass pathway, a formulation container, etc. used herein can be the same as Preparation Method A, unless otherwise indicated.
- pH, temperature, liquid volume ratio, stirring speed, dropping speed, circulation velocity, etc. used herein are also the same as Preparation Method A, unless otherwise indicated.
- the present compound is dissolved in water, an organic solvent or a mixture thereof with a surfactant to prepare a solution of the active ingredient.
- a water solution comprising a surfactant and a buffer is prepared to give a crystallizing agent.
- the crystallizing agent is injected into a vessel for crystallization.
- the vessel for crystallization used herein is equipped with a stirring system, whose internal capacity is big enough to contain a solution of the active ingredient and the crystallizing agent.
- the material of the vessel for crystallization includes a stainless vessel (e.g. SUS304, SUS316, SUS316L).
- the stirring system set in the vessel for crystallization includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings), a homomixer, a static mixer and a stirring bar for a magnetic stirrer.
- the solution of the active ingredient prepared in step (1) is dropped into the vessel for crystallization containing the water solution prepared in step (2) (crystallizing agent).
- the volume ratio between the crystallizing agent and the solution of the active ingredient is about 1:0.1 to about 1:10, preferably about 1:0.2 to about 1:2.
- the present compound is crystallized in this step.
- the precipitated crystal is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2.
- the mean particle size of the crystal can be controlled by adjusting the crystallizing temperature, stirring speed, dropping rate, etc., or by adjusting the circulation velocity when using the bypass pathway mentioned below.
- the solution of the active ingredient prepared in step (1) can be added dropwise thereto and simultaneously circulating the solution in the vessel for crystallization via a bypass pathway.
- the bypass pathway has a pump which can pressure a solution in the pathway.
- pump which can pressure a solution includes, for example, a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump), preferably a roller pump.
- one embodiment of the device which can be used in the crystallizing process of the present invention includes a device equipped with (1) a vessel for crystallization which has a stirring part and can contain a solution of the active ingredient and a crystallizing agent, (2) a bypass pathway connected to the vessel for crystallization which can make a solution in the vessel for crystallization circulated, and (3) a pump set in the bypass pathway which can pressure the solution.
- the bypass pathway can connect, for example, from the vessel for crystallization to the pump, and from the pump to the vessel for crystallization, with tube, pipe, etc.
- the tube includes, for example, but not limited to, silicone tube, flexible polyvinyl chloride tube, polyurethane tube, fluoro-rubber tube, and olefinic tube, and preferably silicone tube.
- the circulation velocity in the bypass pathway is preferably about n ⁇ 0.001 L/min to about n ⁇ 2 L/min, more preferably about n ⁇ 0.01 L/min to about n ⁇ 1 L/min wherein “n” denotes the total volume of the crystallizing agent and the solution of the active ingredient.
- the circulation velocity is about 1 mL/min to about 2000 mL/min, preferably about 10 mL/min to about 1000 mL/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1 L; about 100 mL/min to about 200 L/min, preferably about 1 L/min to about 100 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 100 L; and about 1 L/min to about 2000 L/min, preferably about 10 L/min to about 1000 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1000 L.
- the crystal precipitated in step (3) is collected through a filter.
- the crystal produced under the condition of in step (3) such as crystallizing temperature, circulation velocity and stirring speed has almost uniform mean particle sizes. The method therefore can prepare a crystal having uniform mean particle sizes without any milling steps.
- a water solution comprising a surfactant, a buffer, an isotonic agent, and water for injection is prepared.
- the vehicle solution may further comprise a pH regulator, a soothing agent, a water-soluble polymer, and other polymers, etc.
- the crystal of step (4) is washed. The washing process may be repeated several times. After washing the crystal, the vehicle solution can be put into the vessel again and mixed with the crystal to provide a suspension formulation which is the formulation of the invention.
- the active ingredient prepared in step (4) may be continuously suspended in the vehicle solution to provide an injectable product (suspension formulation), and additionally, the active ingredient obtained from the crystallization may be washed with water, an organic solvent or a mixture thereof, and then dried for a while and suspended in the vehicle solution again to prepare a suspension formulation.
- the suspension formulation prepared in Step (5) can be formed as a prefilled formulation through the following step (6).
- the suspension formulation prepared in Step (5) is put into a container for formulation such as a prefilled syringe, a vial, an ampule, a bag or a Blow-Fill-Seal container.
- the preferred container includes a prefilled syringe and a vial.
- the prefilled formulation of the suspension (i.e. container filled with the suspension) prepared in step (6) is sterilized by a process of steaming under pressure.
- the process can make the level of sterile assurance enhanced.
- the temperature of the steam sterilization under pressure is preferably 100-150° C., more preferably 115-141° C., and even more preferably 115-126° C.
- the time for the steam sterilization under pressure can be suitably decided, for example, 1-120 min, more preferably 5-60 min, even more preferably 10-40 min.
- the prefilled formulation of the suspension i.e. container filled with the suspension prepared in step (6) or (7) is ultrasonicated.
- the process can make the uniformity enhanced to enhance the re-suspensiblility when used.
- the frequency of the ultrasonication is preferably 10-200 kHz, more preferably 20-100 kHz, and even more preferably 25-80 kHz.
- the time for the ultrasonication can be suitably decided, for example, 0.1-120 min, more preferably 0.1-60 min, even more preferably 0.1-30 min.
- step (7) it is possible to do any one of the above steps (7) and (8) or both as needed.
- step (8) it is preferred to do step (8) to uniform the suspension since the active ingredient (free form of Compound 1) contains macroaggregated particles generated due to secondary aggregation (see, for example, Example A2, FIGS. 4 and 5 mentioned below).
- Steps (1)-(6) defined in Preparation Method A are carried out and further any one or both of Step (7) and (8) defined in Preparation Method B are carried out.
- Step (7) the level for aseptic assurance of the final product can be ensured since Steps (1)-(6) are aseptically carried out, and further the product prepared in Steps (1)-(6) is sterilized by a process of steaming under pressure in Step (7).
- Tables 1 and 2 show some typical examples of the sustained release formulation for injection.
- the examples listed in Tables 1 and 2 including examples which have combinations of the amount of each ingredient are preferable, but the scope of the present invention is not limited thereto.
- a pressurized filter system SUS316; model: SF-145, ADVANTEC
- a vehicle solution (about pH 7) comprising sterilely-filtered 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v) polysorbate 80 was sterilely injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation.
- the injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1.
- Example 1 According to substantially the same procedure as described in Example 1 [Steps (3) to (5)] except that the stirring speed of the magnetic stirrer was 675 rpm, using 500 g of the crystallizing agent and 500 mL of the solution of the active ingredient which were prepared in Example 1, 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared.
- the injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1.
- Example 1 According to substantially the same procedure as described in Example 1 [Steps (3) to (5)] except that the stirring speed of the magnetic stirrer was 400 rpm, using 500 g of the crystallizing agent and 500 mL of the solution of the active ingredient which were prepared in Example 1, 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared.
- the injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1.
- Table 3 shows the formulation compositions of Formulations No. 1 to No. 3 which were respectively prepared in Examples 1 to 3.
- the particle size distribution was determined as a volume basis with a laser diffraction particle size analyzer (model: SALD-3000, Shimadzu Corporation) by wet method using water as a dispersion medium (refractive index: 2.40-0.20 i).
- the resulting particle size was expressed as a mean particle size (D50) based on its median diameter.
- Table 4 shows the particle size distributions (D10, D50, D90) of Formulations No. 1 to No. 3.
- the particle size distributions were 5.6 ⁇ m (D10), 7.6 ⁇ m (mean particle size D50), and 11.7 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- sustained-release formulations for injection in Table 1 were prepared by adjusting the volume of the vehicle solution so that the concentration of the active ingredient could be adapted for the desired value.
- Example 6 To a 1 L glass bottle [model: GLS-80 DURANTM, SCHOTT; with a teflon stirring bar ( ⁇ 15 mm ⁇ 70 mm)] whose inside is sterilized, 400 g of the crystallizing agent prepared in Example 6 was sterilely injected. Then, the solution of the active ingredient prepared in Example 6 was sterilely added dropwise at a flow rate of 40 mL/min for 10 minutes to the glass bottle wherein the crystallizing temperature was controlled at 50° C. while stirring with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 400 rpm to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of Compound 1.
- Compound 1 was milled with a Pin Mill (model AVIS-100, DALTON) at a blade rotational speed of 14000 rpm to give a milled active ingredient.
- a Pin Mill model AVIS-100, DALTON
- the concentration of the active ingredient was adjusted by changing the injection volume of the vehicle solution to give the 400 mg/mL sustained-release formulation for injection defined in Table 1.
- the 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared, which is also the same as the formulation defined in Table 3.
- the particle size distribution was 20.8 ⁇ m (D10), 54.3 ⁇ m (mean particle size D50), and 130.3 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the sterile formulation of the present invention can be prepared through the non-sterile process of any one of Examples 1 to 11, and then steam sterilization under pressure and ultrasonication (according to, for example, the method of Example A1, B3 or B4).
- a vehicle solution (about pH 7) comprising sterilely-filtered 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v) polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation.
- the injection volume of the vehicle solution was decided according to Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 100, 150 and 200 mg/mL sustained-release formulation for injection defined in Table 1.
- Each 2 mL of the sustained release formulations for injection wherein the concentrations of the active ingredient are 100, 150, and 200 mg/mL were put into each 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vials were sealed with a rubber stopper and a cap.
- One mL prefilled syringe (model: V-OVS System 10.6 rubber formulation 40, VETTER) was filled with 1 mL of the sustained release formulation for injection wherein the concentration of the active ingredient is 150 mg/mL and sealed with a rubber stopper (ST-W 1 mL, VETTER).
- the vials and the prefilled syringe were sterilized at 121° C.
- the particle size distribution was 5.6 ⁇ m (D10), 10.3 ⁇ m (mean particle size D50) and 16.9 ⁇ m (D90) in 100 mg/mL formulation laded in vial; 5.6 ⁇ m (D10), 8.6 ⁇ m (mean particle size D50) and 13.1 ⁇ m (D90) in 150 mg/mL formulation laded in vial; 5.7 ⁇ m (D10), 8.7 ⁇ m (mean particle size D50) and 13.9 ⁇ m(D90) in 200 mg/mL formulation laded in vial; and 9.9 ⁇ m (D10), 22.1 ⁇ m (mean particle size D50) and 43.2 ⁇ m (D90) in 150 mg/mL formulation laded in prefilled syringe, which were determined by using the method measuring particle size distributions defined in Example 4.
- sustained release formulation for injection comprising 150 mg/mL crystalline active ingredient which was just sterilized with a high-pressure steam sterilizer in Example A1
- non-ultrasonicated formulation FIG. 4
- ultrasonicated formulation 35 kHz, 3 min
- FIG. 5 Using the sustained release formulation for injection (in vial) comprising 150 mg/mL crystalline active ingredient which was just sterilized with a high-pressure steam sterilizer in Example A1, (i) non-ultrasonicated formulation ( FIG. 4 ), and (ii) ultrasonicated formulation (35 kHz, 3 min) ( FIG. 5 ) were stirred for 30 sec with a vortex mixer (model: MT-51, Yamato), and transferred each to 35 mm polystyrene plate (model: 1000-035, IWAKI). The formulations were observed with the naked eye if they contain macroaggregated particles.
- the sustained release formulation for injection (in vial) comprising 150 mg/mL crystalline active ingredient which was prepared in Example A1
- the powder X-ray diffraction was measured (i) before the steam sterilization under pressure, and (ii) after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min).
- the crystal of the active ingredient was washed with water for injection (Otsuka Parmaceutical) and dried in air overnight. The resulting dried crystal powder was put on the top of a sample holder and the surface thereof was smoothed with a glass slide.
- the sustained release formulation for injection comprising 150 mg/mL crystalline active ingredient
- the result of X-ray diffraction in the sample before the steam sterilization under pressure is shown in Table 5 and FIG. 6
- the result of X-ray diffraction in the sample after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min) is shown in Table 6 and FIG. 7 .
- the values of diffraction peaks at diffraction angle 2 ⁇ (°) can include a little measurement errors according to a measurement device or a measurement condition.
- the measurement error may be ⁇ 0.2, preferably ⁇ 0.1.
- the crystallizing agent 500 mL was injected into the 1 L glass separable flask.
- the solution of the active ingredient was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 400 rpm with a stirring machine (model: FBL1200, Shinto Scientific) for 25 min to give a crystal slurry of the active ingredient.
- the crystal in the crystal slurry was a mixture of a cubic-shaped crystal and an amorphous form which was a free form of Compound 1.
- the crystallizing agent (500 mL) prepared in Example B1 was injected into the 1 L glass separable flask. Then, the solution of the active ingredient prepared in Example B1 was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 400 rpm with a stirring machine (model: FBL1200, Shinto Scientific) for 25 min and simultaneously circulating the solution for 25 min or more at a circulation velocity of 600 mL/min (roller pump, flow rate: 150 mL/min ⁇ 4 pump heads, model: 7523-00, Cole-Parmer) via the above bypass pathway to give a crystal slurry of the active ingredient.
- the crystal in the crystal slurry was a cubic-shaped crystal which was a free form of Compound 1.
- the crystallizing agent (15 kg) was injected into the vessel. Then, maintaining the sealed state of the vessel, the solution of the active ingredient was added dropwise at a flow rate of 600 mL/min to the vessel wherein the crystallizing temperature was controlled at around 25° C.
- Example 1 The substantially same process as Example 1 (Steps 4-5) was done by adjusting the volume of the vehicle solution to adjust the concentration of the active ingredient, to prepare a sustained release formulation for injection which contains each ingredient used in the vehicle solution shown in Table 7 that was calculated based on the density of the formulation and 150 mg/mL crystal of the active ingredient.
- Two mL of the sustained release formulations for injection wherein the concentration of the active ingredient is 150 mg/mL was put into 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vial was sealed with a rubber stopper and a cap.
- the vial was sterilized at 121° C. for 20 min with a high-pressure steam sterilizer (type: HG-80, HIRAYAMA). Then, the vial was treated for 3 min with an ultrasonicator (model: UT-605HS, SHARP) at 35 kHz.
- the particle size distribution was 12.4 ⁇ m (D10), 16.7 ⁇ m (mean particle size D50) and 21.9 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the crystallizing agent 50 kg was injected into the vessel. Then, the solution of the active ingredient was added dropwise at a flow rate of 2 L/min to the vessel wherein the crystallizing temperature was controlled at around 25° C.
- the crystal in the crystal slurry was a cubic-shaped crystal which was a free form of Compound 1.
- Example 1 The substantially same process as Example 1 (Steps 4-5) was done by adjusting the volume of the vehicle solution to prepare a sustained release formulation for injection which contains each ingredient used in the vehicle solution shown in Table 7 that was calculated based on the density of the formulation and 150 mg/mL crystal of the active ingredient.
- Two mL of the sustained release formulations for injection wherein the concentration of the active ingredient is 150 mg/mL was put into 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vial was sealed with a rubber stopper and a cap.
- the vial was sterilized at 121° C. for 20 min with a high-pressure steam sterilizer (type: HG-80, HIRAYAMA). Then, the vial was treated for 3 min with an ultrasonicator (model: UT-605HS, SHARP) at 35 kHz.
- the particle size distribution was 14.3 ⁇ m (D10), 17.9 ⁇ m (mean particle size D50) and 23.0 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the crystallizing process was carried out while circulating the solution via the bypass pathway connected to the vessel for crystallization, and it was possible to reproducibly prepare a cubic crystal thereof with a pump in the bypass pathway such as a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump) even when a large-scale preparation.
- a pump in the bypass pathway such as a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump) even when a large-scale preparation.
- the crystallizing agent 500 mL was injected into the 1 L glass separable flask. Then, the solution of the active ingredient was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C.
- a pressurized filter system SUS316; model SF-145, ADVANTEC
- the particle size distribution was 5.5 ⁇ m (D10), 10.5 ⁇ m (mean particle size D50) and 18.9 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- Example C1 The substantially same process as Example C1 was done by changing the concentration of ethanol used as a water-containing alcohol solvent from 0% to 100% to prepare a cubic-shaped crystal of the active ingredient.
- the weight of the resulting the crystal of the active ingredient (dried weight), the yield per 10.8 g of the starting material, and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 8.
- the content of an organic solvent in the mixture of an organic solvent and water to prepare the solution of the active ingredient was preferably 40 to 90%, more preferably 60 to 80%.
- aqueous 70% ethanol solution was the most preferred.
- a SUS316 pressurized filter system model SF-145, ADVANTEC
- a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.005% (w/v) polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation.
- the injection volume of the vehicle solution was decided according to “300 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 300 mg/mL sustained-release formulation for injection defined in Table 1.
- the particle size distribution was 9.0 ⁇ m (D10), 18.3 ⁇ m (mean particle size D50) and 30.6 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- Example D1 The substantially same process as Example D1 was done by using the crystal of the active ingredient prepared in Example D1 and changing the concentration of polysorbate 80 used in the vehicle solution from 0.01% (w/v) to 0.10% (w/v) to prepare a sustained release formulation for injection which contains 300 mg/mL cubic-shaped crystal of the active ingredient [Examples D2-D5].
- the particle size distribution of the resulting formulations which was measured according to the method of Example 4 is shown in Table 9.
- Example D1 the substantially same process as Example D1 was done by changing the concentration of polysorbate 80 used in the vehicle solution from 0.5% (w/v) to 2.0% (w/v) to prepare a sustained release formulation for injection which contains a cubic-shaped crystal of the active ingredient [Examples D6-D9; Table 10].
- volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 300 mg/mL (50, 100, 150, 200, 250, 400, 500, 600 mg/mL, etc.) (Examples D2a-D9a; Table 11).
- D7a 1.0 50, 100, 150, 200, 250, 400, 500, 600, etc.
- D8a 1.5 50, 100, 150, 200, 250, 400, 500, 600, etc.
- D9a 2.0 50, 100, 150, 200, 250, 400, 500, 600, etc.
- Step (3) To a 100 mL vial container with a scale attachment [model: WT-110, NICHIDEN-RIKA GLASS; with a teflon stirring bar ( ⁇ 8 mm ⁇ 35 mm)], 50 mL of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise into the glass bottle at a flow rate of 5 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model BS-56L-1, IWAKI) at a stirring speed of 1200 rpm to give a crystal slurry of the active ingredient.
- the crystal in the slurry was a cubic-shaped crystal which was a free form of Compound 1.
- a reduced-pressure-type glass filter system index No. XX1504700, MILLIPORE
- OmniporeTM membrane filter pre-attached to the filter system
- Step (5) To the crystal of the active ingredient which was collected on the filter, a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v) polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. A sustained-release formulation for injection containing 200 mg/mL the active ingredient was prepared by adjusting the volume of the vehicle solution. The particle size distribution was 7.5 ⁇ m (D10), 9.8 ⁇ m (mean particle size D50) and 13.1 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example E1a].
- the polysorbate 80 contained in the vehicle solution can be replaced with polysorbate 20 and the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) [Example E1b].
- the surfactant (polysorbate 20) used in the solution of the active ingredient (Step (1)) and the crystallizing agent (Step (2)) in Example E1 were replaced with any other surfactant in the same concentration such as polyoxyethylene hydrogenated castor oil 50 [Example E2], polyoxyethylene hydrogenated castor oil 60 [Example E3], poloxamer 188 [Example E4], polyoxyethylene castor oil [Example E5], benzalkonium chloride [Example E6], sodium lauryl sulfate [Example E7], and additive-free (0%) [Example E8], and then the substantially same process as Example E1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient.
- the surfactant used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 12.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.)(Table 13).
- Example E1 the polysorbate 80 used in the vehicle solution (Step (5)) in Example E1 was replaced with any other surfactant in the same concentration such as polyoxyethylene hydrogenated castor oil 50 [Example E2b], polyoxyethylene hydrogenated castor oil 60 [Example E3b], poloxamer 188 [Example E4b], polyoxyethylene castor oil [Example E5b], benzalkonium chloride [Example E6b], and sodium lauryl sulfate [Example E7b], and then the substantially same process as Step (5) in Example E1 was done adjusting the volume of the vehicle solution to prepare a formulation which contains a cubic-shaped crystal of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 14).
- any other surfactant in the same concentration such as polyoxyethylene hydrogenated castor oil 50 [Example E2b], polyoxyethylene hydrogenated castor oil 60 [Example E3b], po
- Example agent each 1% (5) the active No. (w/v) (each 0.2% (w/v) ingredient (mg/mL)
- E1b polysorbate 20 polysorbate 20 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- a reduced-pressure-type glass filter system index No. XX1504700, MILLIPORE
- OmniporeTM membrane filter pre-attached to the filter system
- a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.2% (w/v) polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation.
- the injection volume of the vehicle solution was decided according to “200 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 200 mg/mL sustained-release formulation for injection defined in Table 1.
- the particle size distribution was 6.3 ⁇ m (D10), 10.2 ⁇ m (mean particle size D50), 16.7 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example F1a].
- the 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride) contained in the vehicle solution can be replaced with potassium dihydrogenphosphate/dipotassium hydrogen phosphate in order to adjust pH to around 7, and the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) [Example F1b].
- Example F1 The 50 mmol/L dipotassium hydrogen phosphate (buffer) used in the crystallizing agent in Example F1 was replaced with any other buffer in the same mole concentration (mol/L) or a pH regulator such as arginine [Example F2], trometamol [Example F3], sodium carbonate [Example F4], triethanolamine [Example F5], meglumine [Example F6], sodium hydroxide [Example F7], and disodium hydrogenphosphate [Example F8]) and then the substantially same process as Example F1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient.
- the buffer used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 15.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.)(Table 16).
- Example F1 the buffer [0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)] used in the vehicle solution in Example F1 was replaced with any other buffer such as L-arginine hydrochloride/L-arginine (pH: about 7) [Example F2b], trometamol (pH: about 7) [Example F3b], sodium hydrogen carbonate/sodium carbonate (pH: about 7) [Example F4b], triethanolamine (pH: about 7) [Example F5b], and meglumine (pH: about 7) [Example F6b]), and then the substantially same process as Example F1 was done adjusting the volume of the vehicle solution to prepare a formulation which contains a cubic-shaped crystal of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 17).
- any other buffer such as L-argin
- Example agent Buffer in the crystallizing Concentration of Example agent Buffer in the active No. each 50 mmol/L vehicle solution ingredient (mg/mL)
- F1b dipotassium potassium 50 100, 150, 200, hydrogen dihydrogen- 250, 300, 400, phosphate phosphate/ 500, 600, etc. dipotassium hydrogen phosphate
- F2b arginine L-arginine 50 100, 150, 200, hydrochloride/L- 250, 300, 400, arginine 500, 600, etc.
- the 0.70% (w/v) sodium chloride (isotonic agent) used in the vehicle solution in Example F1 can be replaced with any other isotonic agent such as D-mannitol [about 5% (w/v); Example F9], D-fructose [about 5% (w/v); Example F10], D-xylitol [about 5% (w/v); Example F11], D-sorbitol [about 5% (w/v); Example F12], D-lactose [about 10% (w/v); Example F13], D-glucose [about 5% (w/v); Example F14], D-trehalose [about 10% (w/v); Example F15], and D-sucrose [about 10% (w/v); Example F16] and D-maltose [about 5% (w/v); Example F17]) to prepare a sustained release formulation for injection of the present invention.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100
- F12 D-sorbitol about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- F13 D-lactose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- F14 D-glucose about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- F15 D-trehalose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- F16 D-sucrose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- F17 D-maltose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc.
- Lidocaine hydrochloride [about 0.5% (w/v) ⁇ 2% (w/v)] can be additionally contained in the vehicle solution prepared in Example F8 and the volume of the vehicle solution can be adjusted to prepare a formulation of lidocaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- Lidocaine hydrochloride described in Example F17 can be replaced with procaine hydrochloride [about 0.5% (w/v)-2% (w/v)] and the volume of the vehicle solution can be adjusted to prepare a formulation of procaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- Lidocaine hydrochloride described in Example F17 can be replaced with meprylcaine hydrochloride [about 1% (w/v)-3% (w/v)] and the volume of the vehicle solution can be adjusted to prepare a formulation of meprylcaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- a reduced-pressure-type glass filter system index No. XX1504700, MILLIPORE
- OmniporeTM membrane filter pre-attached to the filter system
- a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/5.0% (w/v) D-mannitol/0.2% (w/v) polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation.
- the injection volume of the vehicle solution was decided according to “200 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 200 mg/mL sustained-release formulation for injection defined in Table 1.
- the particle size distribution was 5.5 ⁇ m (D10), 7.4 ⁇ m (mean particle size D50), 9.4 ⁇ m (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example G1a].
- Example G1 The methanol used in the solution of the active ingredient in Example G1 was replaced with any other organic solvent such as acetone [Example G2], N,N-dimethylacetamide [Example G3], 1-propanol [Example G4], 2-propanol [Example G5], and dimethylsulfoxide [Example G6]) and then the substantially same process as Example G1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient.
- the solvent used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 19.
- the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 20).
- Table 21 shows the formulation composition of Formulations No. 4 to No. 6, wherein all of the formulations have 200 mg/mL of the active ingredient.
- Table 22 shows the obtained particle size distributions (D10, D50, D90) of Formulations No. 4 to 6 which were determined by the measurement method of particle size distribution described in Example 4.
- the mean particle sizes were 5.0 ⁇ m (Formulation No. 4), 11.3 ⁇ m (Formulation No. 5), and 25.8 ⁇ m (Formulation No. 6).
- Each of the formulations having 200 mg/mL of the active ingredient was administered to gastrocnemius muscle of six rats [Sprague-Dawley rats (SD), male, 9 weeks old, 250-300 g] in a dose of 50 mg/kg (0.25 mL/kg).
- the blood was collected 1, 2, and 4 hours, 1, 2, 4, 7, 14, 21, and 28 days after the administration, and the results showed that the blood level of the present compound held up well.
- the mean particle size was 5.0 ⁇ m (Formulation No. 4)
- the present compound rapidly disappeared from the blood after 7 days (1 week); whereas in case that the mean particle size was 11.3 ⁇ m (Formulation No. 5) and 25.8 ⁇ m (Formulation No. 6), the blood level of the present compound held up well for at least 14 days (2 weeks).
- Table 23 shows the formulation composition of Formulations No. 7 to No. 10, wherein all of the formulations have 400 mg/mL of the active ingredient.
- Table 24 shows the obtained particle size distributions (D10, D50, D90) of Formulations No. 7 to 10 which were determined by the measurement method of particle size distribution described in Example 4.
- the mean particle sizes were 4.8 ⁇ m (Formulation No. 7), 11.1 ⁇ m (Formulation No. 8), 20.0 ⁇ m (Formulation No. 9), and 11.7 ⁇ m (Formulation No. 10).
- each of the formulations having 400 mg/mL of the active ingredient was administered to gastrocnemius muscle of six rats [Sprague-Dawley rats (SD), male, 9 weeks old, 250-300 g] in a dose of 100 mg/Kg (0.25 mL/kg).
- the blood was collected 1, 2, and 4 hours, 1, 2, 4, 7, 14, 21, and 28 days after the administration, and the results showed that the blood level of the present compound held up well.
- the mean particle size was 4.8 ⁇ m (Formulation No. 7)
- the present compound rapidly disappeared from the blood after 7 days (1 week); whereas in case that the mean particle size was 11.1 ⁇ m (Formulation No. 8), 20.0 ⁇ m (Formulation No. 9) and 11.7 ⁇ m (Formulation No. 10)
- the blood level of the present compound held up well for at least 14 days (2 weeks).
- Each of the active ingredient crystals having the following mean particle size:
- formulations of the crystal which have a concentration of 200-400 mg/mL with a 10 mg/mL interval were prepared with the crystals having a mean particle size of 11.1-84.9 ⁇ m.
- Each formulation was injected into the melamine form used in Example 14, and the needle passability was evaluated by judging whether the whole amount of each formulation could be injected or not (i.e. whether the needle's inside is clogged with the crystal or not).
- Table 27 shows the results of these.
- ⁇ shows that it is possible to inject the whole amount of the formulation into the melamine form
- x shows that it is difficult to inject them
- the results are as follows:
- the present invention can get more patients effectively treated because the present compound in the present formulation can be continuously released for at least more than 2 to 4 weeks, and the present compound can be also formulated into a sustained release formulation for injection which has a good needle passability.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof. In detail, the composition relates to a sustained release formulation for injection which maintains an effective blood level of the above-mentioned compound.
Description
- The present application is a divisional of U.S. application Ser. No. 15/043,235, filed Feb. 12, 2016, which is a Divisional of U.S. application Ser. No. 13/276,039, filed Oct. 18, 2011, now U.S. Pat. No. 9,469,630, issued Oct. 18, 2016, which is based upon and claims the benefits of priority to U.S. Provisional Application No. 61/394,069, filed Oct. 18, 2010. The entire contents of all of the above applications are incorporated herein by reference.
- The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl] (1′R,2′S, 3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof (hereinafter, optionally referred to as “the present compound”). To be more specific, the present invention relates to a sterile suspension formulation which can maintain an effective blood level of the present compound as a sustained release formulation for injection. Furthermore, the present invention relates to a process of the formulation comprising the present compound.
- It is known that N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl] (1′R,2′S,3′R, 4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide hydrochloride (hereinafter, optionally referred to as “
Compound 1”) has psychotropic activity and is useful as a therapeutic agent for diseases such as schizophrenia. -
Patent Reference 1 describes thatCompound 1 is usually administered orally. - It is known that risperidone, olanzapine, aripiprazole, etc. have been already used in clinical practice as an agent for treating schizophrenia or other similar diseases. In order to promote patient compliance and reduce the relapse rate of schizophrenia, these medicaments for treating schizophrenia are desired to be modified to exert a long-term effect through a single administration.
- A depot formulation for intramuscular injection comprising an injectable suspension of a medicament is generally known as one of administration means for sustained-release of a medicament. An injectable suspension is in a heterogeneous system comprising a solid phase dispersed in an aqueous or nonaqueous liquid phase, which requires sterile, stable, resuspendable, syringeable, injectable, isotonic, and nonirritating. In order to develop such depot formulation, in particular, it is necessary at least that such formulation is an aqueous one and additionally has satisfactory properties for an injectable suspension such as uniformity of dispersed particles of an active ingredient, sedimentation property of dispersed particles after still standing, re-suspensibility, and permeability in a needle (hereinafter, optionally referred to as “suspensibility”). In order to satisfy these requirements, for example,
Patent Reference 2 discloses a composition comprising microparticles comprising a polymeric binder, and an aqueous injectable vehicle. The composition has a constructional property wherein the microparticles have a mass median diameter of at least about 10 μm, and the vehicle comprises a viscosity enhancing agent. - However, many of medicaments for treating schizophrenia or other similar diseases are hardly water-soluble, thus it is not easy to develop such formulation thereof which can make these requirements satisfied.
- For example, a formulation comprising aripiprazole makes such requirements satisfied by reducing the mean particle size of the compound and adding a specific suspending agent such as carboxymethylcellulose thereto (Patent Reference 3). And, a formulation comprising olanzapine makes such requirements satisfied by further reducing the size of the compound to nanoparticles and using a surface stabilizer such as polysorbate (Patent Reference 4). As just described, in order to prepare a suspension comprising such hardly water-soluble compound, it is necessary to select an adaptable means in response to the property of the active ingredient after studying various means to meet the requirements.
- To prepare a formulation for injection, some extra processes such as sterilization and dust free in a clean room are also required. In particular, a process under aseptic atmosphere is generally accompanied with some complicated and troublesome steps and manufacturing-operations. In addition, to comply with the predetermined level for assurance of aseptic preparation, some strict controls such as sterilization of apparatuses and devices, education and training for operators, and control of the number of environmental microbials and microparticles in an aseptic plant are also required.
- [Patent Reference 1] JP Patent No. 2800953
- [Patent Reference 2] JP 2003-534366 T
- [Patent Reference 3] JP 2007-509148 T
- [Patent Reference 4] JP 2008-520581 T
- Taking these conventional/current techniques into consideration, the present inventors attempted to improve the drug delivery property of Compound 1 as a medicament for treating schizophrenia or other similar diseases and tried finding an injectable suspension formulation which would satisfy the desired suspensibility.
Compound 1 has a low solubility in water, and exhibits poor water solubility and hydrophobicity. This means that it is technically difficult to formulate the compound as an injectable product. To be more specific, whenCompound 1 is dispersed in water, the particles thereof tend to come up to the surface or adhere to the container wall, and thus it was difficult to satisfy the suspensibility as an injectable suspension product. As a general technique to prepare an injectable suspension product with a sustained release property,Patent Reference 4 teaches that the releasing time can be adjusted by optimally controlling the particle size and it is preferred to keep the mean particle size of an active ingredient as small as possible. As forCompound 1, however, when the mean particle size thereof was too small, the sustained release for a long period could not be attained; whereas when the particles of bigger mean particle size were used so that the sustained release for a long period could be attained, then an injection needle was clogged with the particles, thus it was found that such bigger particles was difficult for be injected. - A problem to be solved by the invention is to provide a formulation that can maintain an effective blood level of the present compound for a long period (hereinafter, optionally referred to as “the present formulation”). In addition, the invention is intended to provide a process to accurately control the particle size of the present compound (hereinafter, optionally referred to as “the present process”). Furthermore, the invention is intended to provide a sterile and dust-free suspension formulation which can be easily processed without using complicated dosage forms and/or complicated processes.
- The present inventors have extensively studied to reach the above object and have surprisingly found that the above-mentioned problems could be solved by using a specific mean particle size of the present compound, a specific nonionic surfactant, and an active ingredient having an optimized concentration. The prepared suspension formulation for injection thereby exhibits a good suspensibility and is able to pass through an injection needle easily. Based upon the new findings, the present invention has been completed.
- The present inventions are as follows:
- A composition comprising the following (1) to (5),
- (1) N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof as an active ingredient,
- (2) a surfactant comprising at least one ingredient selected from the group consisting of
polysorbate 80,polysorbate 20, polyoxyethylene hydrogenatedcastor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188 and polyoxyethylene castor oil, - (3) a buffer comprising at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid,
- (4) an isotonic agent comprising at least one ingredient selected from the group consisting of sodium chloride and D-mannitol, and
- (5) water for injection.
- The composition of
Term 1 wherein the active ingredient is in a crystal form. - The composition of
Term 2 wherein the mean particle size of the crystal is about 4 μm-about 55 μm, about 4 μm-about 26 μm, about 4 μm-about 20 μm, about 4 μm-about 18 μm, about 4 μm-about 16 μm, about 5 μm-about 55 μm, about 5 μm-about 26 μm, about 5 μm-about 20 μm, about 5 μm-about 18 μm, about 5 μm-about 16 μm, about 8 μm-about 55 μm, about 8 μm-about 20 μm, about 10 μm-about 55 μm, about 10 μm-about 26 μm, about 10 μm-about 20 μm, about 10 μm-about 18 μm, or about 10 μm-about 16 μm. - The composition of Term 3 wherein the mean particle size of the crystal is about 5 μm-about 55 μm.
- The composition of Term 3 wherein the mean particle size of the crystal is about 5 μm-about 26 μm.
- The composition of Term 3 wherein the mean particle size of the crystal is about 5 μm-about 20 μm.
- The composition of Term 3 wherein the mean particle size of the crystal is about 5 μm-about 16 μm.
- The composition of Term 3 wherein the mean particle size of the crystal is about 10 μm-about 20 μm.
- The composition of Term 3 wherein the mean particle size of the crystal is about 10 μm-about 16 μm.
- The composition of any one of
Terms 2 to 9 wherein the crystal is a cubic crystal. - The composition of
Term 10 wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2. - The composition of any one of
Term 2 to 11 wherein the active ingredient in crystal form is contained in about 5% (w/v) to about 60% (w/v) per the whole of the composition. - The composition of any one of
Terms 1 to 12 wherein the surfactant ispolysorbate 80. - The composition of any one of
Terms 1 to 13 wherein the surfactant is contained in about 0.005% (w/v) to about 2% (w/v) per the whole of the composition. - The composition of any one of
Terms 1 to 14 wherein the buffer is at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid. - The composition of Term 15 wherein the buffer is sodium dihydrogenphosphate and/or disodium hydrogenphosphate.
- The composition of any one of
Terms 1 to 16 wherein the buffer is contained in about 0.01% (w/v) to about 2% (w/v) per the whole of the composition. - The composition of any one of
Terms 1 to 17 wherein the isotonic agent is sodium chloride. - The composition of any one of
Terms 1 to 18 wherein the isotonic agent is contained in about 0.1% (w/v) to about 10% (w/v) per the whole of the composition. - A sustained release formulation for injection which comprises the composition according to any one of
Terms 1 to 19. - The formulation of
Term 20 wherein the active ingredient is contained in a concentration of about 50 mg/mL to about 600 mg/mL. - The formulation of
Term 21 wherein the active ingredient is contained in a concentration of about 50 mg/mL to about 400 mg/mL. - The formulation of
Term 22 wherein the active ingredient is contained in a concentration of about 100 mg/mL to about 400 mg/mL. - The formulation of
Term 23 wherein the active ingredient is contained in a concentration of about 100 mg/mL to about 200 mg/mL. - The formulation of
Term 23 wherein the active ingredient is contained in a concentration of about 200 mg/mL to about 400 mg/mL. - The formulation of any one of
terms 20 to 25 wherein the surfactant is contained in a concentration of about 0.05 mg/mL to about 20 mg/mL. - The formulation of any one of
Terms 20 to 26 wherein the buffer is contained in a concentration of about 0.1 mg/mL to about 20 mg/mL. - The formulation of any one of
Terms 20 to 27 wherein the isotonic agent is contained in a concentration of about 1 mg/mL to about 100 mg/mL. - The formulation of any one of
Terms 20 to 28 which contains about 50 mg to about 1200 mg of the active ingredient per a container. - The formulation of Term 29 which contains about 100 mg to about 800 mg of the active ingredient per a container.
- The formulation of any one of
Terms 20 to 30 which can pass through a needle of 18 to 23 gauges. - The formulation of any one of
Terms 20 to 31 wherein the sustained release formulation for injection is a depot formulation for injection. - A process of a sustained-release sterile formulation for injection comprising the following steps (1) to (5):
- step (1): dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water, and then sterilely-filtering the solution,
- step (2): preparing a water solution comprising a surfactant and a buffer, sterilely filtering the water solution, and then sterilely putting the water solution into a sealed vessel whose inside is sterilized,
- step (3): sterilely adding the sterile solution prepared in step (1) into the sealed vessel containing the water solution prepared in step (2),
- step (4): collecting a crystal precipitated in step (3) through a filter in the sealed vessel, and
- step (5): preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection, sterilely filtering the water solution, and then sterilely putting the water solution into the sealed vessel containing the crystal in step (4) and mixing the water solution and the crystal.
- A process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1): dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2): preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent),
- step (3): adding the solution of the active ingredient prepared in step (1) into the crystallizing agent in step (2),
- step (4): collecting a crystal precipitated in step (3) through a filter, and
- step (5): preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then mixing the water solution and the crystal of the active ingredient prepared in step (4) to prepare a suspension formulation.
- A process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1): dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2): preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent), and then injecting the water solution into a vessel for crystallization,
- step (3): adding the solution of the active ingredient prepared in step (1) into the vessel for crystallization containing the crystallizing agent in step (2),
- step (4): collecting a crystal precipitated in step (3) through a filter in the vessel for crystallization, and
- step (5): preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then injecting the water solution into the crystal of the active ingredient prepared in step (4) and mixing the water solution and the crystal to prepare a suspension formulation.
- The process of any one of
Terms 33 to 35 further followed by the following steps (6) to (8): - step (6): aseptically filling a formulation container with the suspension formulation prepared in step (5) to prepare a filled suspension formulation,
- step (7): sterilizing the filled suspension formulation prepared in step (6) by a process of steaming under pressure, and
- step (8): ultrasonicating the filled suspension formulation prepared in step (7).
- The process of Term 36 wherein the formulation container is a prefilled syringe or a vial.
- The process of
Term 36 or 37 wherein the temperature of the steam sterilization under pressure is 100 to 150° C. - The process of any one of
Terms 33 to 38, in step (3) the solution of the active ingredient is added to the crystallizing agent in the vessel for crystallization (or the sealed vessel) while circulating the solution (or the suspension solution) in the vessel for crystallization (or the sealed vessel) via a bypass pathway equipped with a pump which can pressure a solution. - The process of any one of
Term 39 wherein the pump in the bypass pathway is any one pump selected from a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump). - The process of
Term 39 wherein the pump in the bypass pathway is a roller pump. - The process of any one of
Terms 39 to 41 wherein the circulation velocity of the bypass pathway is about 0.001 to about 2 parts by volume/min per one part of the total volume of the crystallizing agent and the solution of the active ingredient. - The process of any one of
Terms 39 to 41 wherein the circulation velocity of the bypass pathway is about 0.01 to about 1 parts by volume/min per one part of the total volume of the crystallizing agent and the solution of the active ingredient. - A process of a sustained-release formulation for injection comprising the following steps (1) to (5):
- step (1): dissolving a mixture comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof and a surfactant with an organic solvent or a mixture of an organic solvent and water to prepare a solution of the active ingredient,
- step (2): preparing a water solution comprising a surfactant and a buffer (i.e. a crystallizing agent) and injecting the water solution into a vessel for crystallization equipped with a stirring system,
- step (3): adding the solution of the active ingredient to the crystallizing agent in the vessel for crystallization while circulating the solution (or the suspension solution) in the vessel for crystallization via a bypass pathway equipped with a pump which (i) is connected to the vessel for crystallization, (ii) can make the solution in the vessel for crystallization circulated, and (iii) can pressure the solution,
- step (4): collecting a crystal precipitated in the vessel for crystallization from the solution (or the suspension solution) in step (3) through a filter, and
- step (5): preparing a water solution comprising a surfactant, a buffer, an isotonic agent and water for injection (i.e. a vehicle solution), and then injecting the water solution into the crystal of the active ingredient prepared in step (4) and mixing them to prepare a suspension formulation.
- A process of a sustained-release formulation for injection comprising the following steps (4) to (8):
- step (4): preparing a vehicle solution comprising a surfactant, a buffer, an isotonic agent and water for injection,
- step (5): injecting the vehicle solution in step (4) into a crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide and mixing them to prepare a suspension formulation,
- step (6): aseptically filling a formulation container with the suspension formulation prepared in step (5) to prepare a filled suspension formulation
- step (7): sterilizing the filled suspension formulation prepared in step (6) by a process of steaming under pressure, and
- step (8): ultrasonicating the filled suspension formulation prepared in step (7).
- The process of any one of
Terms 33 to 45 wherein each the surfactant is independently at least one ingredient selected from the group consisting ofpolysorbate 80,polysorbate 20, polyoxyethylene hydrogenatedcastor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride and sodium lauryl sulfate. - The process of any one of
Terms 33 to 46 wherein the organic solvent is at least one solvent selected from the group consisting of 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide and N,N-dimethylacetamide. - Term 48 The process of any one of
Terms 33 to 47 wherein the solvent used in step (1) is a mixture of an organic solvent and water. - The process of Term 48 wherein the mixture solvent is a water-containing alcohol.
- The process of Term 49 wherein the content of alcohol in the water-containing alcohol is 40% to 90%.
- The process of Term 49 wherein the content of alcohol in the water-containing alcohol is 50% to 90%.
- The process of any one of
Terms 33 to 51 wherein the alcohol is ethanol. - The process of any one of
Terms 33 to 52 wherein each the buffer is independently at least one ingredient selected from the group consisting of sodium dihydrogenphosphate, disodium hydrogenphosphate, potassium dihydrogenphosphate, dipotassium hydrogenphosphate, sodium carbonate, triethanolamine, arginine and meglumine. - The process of any one of
Terms 33 to 53 wherein the isotonic agent is sodium chloride and/or D-mannitol. - A sustained release formulation for injection which is prepared through the process of any one of
Terms 33 to 54. - A crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide whose mean particle size is in a range selected from the group consisting of about 4 μm-about 55 μm, about 4 μm-about 26 μm, about 4 μm-about 20 μm, about 4 μm-about 18 μm, about 4 μm-about 16 μm, about 5 μm-about 55 μm, about 5 μm-about 26 μm, about 5 μm-about 20 μm, about 5 μm-about 18 μm, about 5 μm-about 16 μm, about 8 μm-about 55 μm, about 8 μm-about 20 μm, about 10 μm-about 55 μm, about 10 μm-about 26 μm, about 10 μm-about 20 μm, about 10 μm-about 18 μm, and about 10 μm-about 16 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 5 μm-about 55 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 5 μm-about 26 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 5 μm-about 20 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 5 μm-about 16 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 10 μm-about 20 μm.
- The crystal of Term 56 wherein the mean particle size of the crystal is about 10 μm-about 16 μm.
- A crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide (free form of Compound 1) which has a powder X-ray diffraction pattern showing diffraction angle 2θ (°) of 15.1±0.2, 15.5±0.2, 16.3±0.2, 16.6±0.2, 18.0±0.2, and 20.0±0.2.
- A crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide (free form of Compound 1) which has a powder X-ray diffraction pattern showing diffraction angle 2θ (°) of 11.2±0.2, 15.1±0.2, 15.5±0.2, 16.3±0.2, 16.6±0.2, 18.0±0.2, 19.1±0.2, 19.5±0.2, 20.0±0.2, 20.9±0.2, 22.3±0.2, and 26.0±0.2.
- The crystal of any one of Terms 56 to 62 which has a powder X-ray diffraction pattern showing diffraction angle 2θ (°) of 15.1±0.2, 15.5±0.2, 16.3±0.2, 16.6±0.2, 18.0±0.2, and 20.0±0.2.
- The crystal of any one of Terms 56 to 65 wherein the crystal is a cubic crystal.
- The crystal of Term 66 which is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:0.8 to about 1:1.2, and the ratio between length and height thereof is about 1:0.1 to about 1:3.
- A depot formulation for injection comprising the crystal of any one of Terms 56 to 67.
- The depot formulation for injection of Term 68 wherein the crystal is suspended in a medium of the formulation.
- The depot formulation for injection of Term 69 wherein the medium is water.
- The depot formulation for injection of any one of Terms 68 to 70 which further comprises a surfactant, a buffer and an isotonic agent.
- A package containing a container which contains the sustained release formulation for injection comprising the crystal of any one of Terms 56 to 67.
- A method for treating psychiatric disease which comprises administering the formulation of any one of
Terms 20 to 32, 55, and 68 to 71. - The method of Term 73 wherein the psychiatric disease is schizophrenia.
- The method of Term 73 wherein the psychiatric disease is bipolar disorder.
- The method of Term 73 wherein the psychiatric disease is depression.
- The present formulation can maintain an effective blood level of the present compound for at least 2 to 4 weeks or more by intramuscular administration. Consequently, using the present formulation, it is possible to decrease the frequency of administration compared with an oral formulation containing the present compound. The present formulation is injectable (i.e. has a good needle passability) even though the present compound is suspended in the present formulation. The present process provides the formulation to maintain an effective blood level of the present compound for at least 2 to 4 weeks or more by suspending the present compound in the formulation. In addition, the present process is useful in the point that the preparation is carried out under a sequential sterile and/or dust-free processing, further via a continuous formulating process.
-
FIG. 1 shows a photomicrograph of the crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide. -
FIG. 2 is a graph showing a transition of the average concentration of drug in the plasma when the formulation prepared in Example 12 (200 mg/mL) was administered to rats in a dose of 50 mg/kg. -
FIG. 3 is a graph showing a transition of the average concentration of drug in the plasma when the formulation prepared in Example 13 (400 mg/mL) was administered to rats in a dose of 100 mg/kg. -
FIG. 4 is a photograph showing that the non-ultrasonicated formulation prepared in Example A2 contains macroaggregated particles. -
FIG. 5 is a photograph showing that the ultrasonicated formulation (35 kHz, 3 min) prepared in Example A2 contains no macroaggregated particles. -
FIG. 6 is an X-ray diffraction in the sample before the steam sterilization under pressure in Example A3. -
FIG. 7 is an X-ray diffraction in the sample after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min) in Example A3. - The term “active ingredient” used herein is N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof. Preferably, the term refers to N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a hydrochloride thereof. The concentration of the active ingredient used herein is within about 5% (w/v) to about 60% (w/v) per the whole of the formulation as a free form.
- In addition, the concentration of the active ingredient in the formulation is preferably about 50 mg/mL to about 600 mg/mL as a free form, and more preferably about 50 mg/mL to about 400 mg/mL, about 100 mg/mL to about 400 mg/mL, about 100 mg/mL to about 200 mg/mL, or about 200 mg/mL to about 400 mg/mL as a free form.
- The “particle size” is controlled to maintain an effective blood level of the active ingredient for at least two weeks, preferably for at least four weeks. The mean particle size of the “active ingredient” used herein is in a range selected from the group consisting of about 4 μm-about 55 μm, about 4 μm-about 26 μm, about 4 μm-about 20 μm, about 4 μm-about 18 μm, about 4 μm-about 16 μm, about 5 μm-about 55 μm, about 5 μm-about 26 μm, about 5 μm-about 20 μm, about 5 μm-about 18 μm, about 5 μm-about 16 μm, about 8 μm-about 55 μm, about 8 μm-about 20 μm, about 10 μm-about 55 μm, about 10 μm-about 26 μm, about 10 μm-about 20 μm, about 10 μm-about 18 μm, and about 10 μm-about 16 μm. Preferably, the mean particle size is about 5 μm-about 55 μm, about 5 μm-about 26 μm, about 5 μm-about 20 μm, about 5 μm-about 16 μm, about 10 μm-about 20 μm, or about 10 μm-about 16 μm. The term “mean particle size (also referred to as D50)” used herein is defined as a median diameter based on the volume, which was obtained by measuring the particle size distribution through a wet process with a laser diffraction particle size distribution analyzer.
- The term “pharmaceutically acceptable acid addition salt” used herein is defined as an addition salt with an inorganic acid or an organic acid. The inorganic acid includes, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, and sulfuric acid. The organic acid includes, for example, phosphoric acid, acetic acid, oxalic acid, citric acid, malic acid, tartaric acid, maleic acid, and fumaric acid. Preferably, the salt is hydrochloride.
- The “surfactant” is used to improve the suspensibility of the crystal in the present formulation, and is contained in a range of about 0.005 to about 2% (w/v) per the whole of the formulation, preferably about 0.01 to about 1% (w/v). In addition, the surfactant is contained in a concentration of about 0.05 mg/mL to about 20 mg/mL. The surfactant includes, for example,
polysorbate 80,polysorbate 20, polyoxyethylene hydrogenatedcastor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, and polyoxyethylene castor oil. Preferably, the surfactant ispolysorbate 80. In addition, the present invention may contain more than two surfactants. - The “buffer” is used in an appropriate amount to adjust the pH of the aqueous suspension in the present formulation to an injectable range, for example about pH 6 to about
pH 8 and preferably aboutpH 7. The buffer is contained in a range of about 0.01 to about 2% (w/v) per the whole of the formulation, and preferably about 0.05 to about 1% (w/v). In addition, the buffer is contained in a concentration of about 0.1 mg/mL to about 20 mg/mL. The buffer includes, for example, sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine, and citric acid. Preferably, the buffer is sodium phosphate. In addition, the present invention may contain more than two buffers. - The “isotonic agent” is used to adjust the osmotic pressure of the present formulation to an injectable range. The isotonic agent is contained in a range of about 0.1 to 10% (w/v) per the whole of the formulation, preferably about 0.2 to about 5% (w/v). In addition, the isotonic agent is contained in a concentration of about 1 mg/mL to about 100 mg/mL. The isotonic agent includes, for example, sodium chloride, and D-mannitol. Preferably, the isotonic agent is sodium chloride.
- The term “water” used herein is defined as purified water, or the same or a higher grade thereof; and such water needs to be sterilized after dissolving various ingredients therein, or already-sterilized water (e.g. water for injection) is used in the process which is carried out under sterile condition throughout the steps. In addition, the term “water for injection” used herein includes water sterilized through a sterile filter etc. after dissolving substrates or reagents into the above-mentioned “water” (as a starting material).
- As shown in
FIG. 1 , the crystal of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof is characterized by a cubic crystal form just after being prepared through the present process. And then, the crystal might be gradually rounded and transformed into a spherical form during storage. In addition, the cubic crystal used herein includes not only perfect cubic shapes but also cuboidal shapes (e.g. shapes whose ratio between length and width is about 1:0.8 to about 1:1.2, and the ratio between length and height thereof is about 1:0.1 to about 1:3, etc.). - The “sustained release formulation for injection” used herein means a formulation which can maintain the blood level of the active ingredient for at least two to four weeks after intramuscular injection.
- The present formulation may contain other additive agents unless there are any adverse effects on the present invention. The other additive agents includes, for example, pH regulators such as hydrochloric acid, acetic acid, lactic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, and sodium hydroxide; soothing agents such as lidocaine hydrochloride, meprylcaine hydrochloride and procaine hydrochloride; water-soluble polymers such as carboxymethylcellulose sodium, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol,
polyethylene glycol 4000, carboxy vinyl polymer, polypeptide, polyamino acid, dextrin, gum arabic, sodium alginate, pullulan, sodium hyaluronate, sodium chondroitin sulfate, gelatin, collagen, agarose, xanthane gum, gellan gum, tamarind gum, guar gum, carrageenan, locust bean gum, karaya gum, tragacanth gum, tara gum, psyllium seed gum, ghatti gum, curdlan, and pectin; and other polymers such as sulfobutylether β-cyclodextrin, hydroxypropyl β-cyclodextrin, polylysine, polyglutamic acid, chitin, chitosan, polylactic acid, polyglycolic acid and sucrose acetate isobutylate. - The present formulation can be administered parenterally, in particular, intramuscularly or subcutaneously as a sustained release formulation for injection, at a dose of 50 to 1200 mg (preferably 100 to 800 mg) of the active ingredient. The present formulation can be administered once in two to six weeks, preferably once in four to six weeks, and more preferably once in four weeks.
- The present formulation may contain 50 to 1200 mg of the active ingredient per a bottle, and preferably 100 to 800 mg thereof.
- The present formulation can be administered intramuscularly or subcutaneously with a prefilled syringe equipped with a needle which is filled with the present formulation. Alternatively, the present formulation can be administered through the following steps; i.e., from a vial filled with the present formulation, the content is transferred into an injection syringe via a needle and then administered intramuscularly or subcutaneously. Furthermore, the present formulation may be put into a container such as a vial and then lyophilized to give a lyophilize formulation, or the crystal of the active ingredient in the present formulation may be isolated, dried, and then put into a container such as a vial to give a powder-filled formulation. The lyophilize formulation or the powder-filled formulation can be administered intramuscularly or subcutaneously as an injectable suspension which is prepared by putting a suspending solution into the container via a needle just before use. A needle of 18 gauge (internal diameter thereof: 0.90 mm) to 23 gauge (internal diameter thereof: 0.33 mm) may be used for the intramuscular or subcutaneous administration. Furthermore, the container filled with the formulation of the present invention can be set in a needleless syringe which can administer a drug solution in the container by discharging the solution with a pressure prepared by a gas, a detonator, a spring, etc. packed in the syringe device without using any needle to administer the drug solution intramuscularly or subcutaneously. The formulation of the present invention includes a form of liquid such as a suspension which can be put in a formulation container, a form wherein the liquid such as a suspension is already put in a formulation container, and further a form wherein the formulation container containing the liquid is sterilized and/or ultrasonicated.
- The present formulation can be prepared according to, for example, the following steps, but are not limited thereto.
- The present compound is dissolved in water, an organic solvent or a mixture thereof with a surfactant to prepare a solution of the active ingredient. The resulting solution is sterilely filtered through a sterile filter to prepare a sterile solution of the active ingredient. The solvent used herein (water, an organic solvent or a mixture thereof) is preferably an organic solvent or a mixture of an organic solvent and water, more preferably a mixture of an organic solvent and water. Sterile filters are effective not only for sterilely-filtering, but also for removing foreign substances derived from starting materials or foreign substances immixed as a contamination during processing steps. The surfactant includes, for example,
polysorbate 80,polysorbate 20, polyoxyethylene hydrogenatedcastor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride, and sodium lauryl sulfate. In addition, two or more of the surfactants may be used. Preferably, the surfactant ispolysorbate 80. Preferably, the surfactant is contained in about 0.005% (w/v) to about 10% (w/v). - The water used herein is purified water or the same or high level of water, or water for injection.
- The organic solvent includes, for example, alcohol solvents (e.g. methanol, ethanol, etc.), and aprotic solvents (e.g. acetone, dimethylsulfoxide, N,N-dimethylacetamide, etc.). In addition, two or more of the solvents may be used. Preferably, the organic solvent is 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide, or N,N-dimethylacetamide.
- The term “mixture of an organic solvent and water” is defined as a mixed solvent comprising the above-mentioned alcohol solvent and/or the above-mentioned aprotic solvent and water (hereinafter, the mixture of an alcohol solvent and water is optionally referred to as “water-containing alcohol solvent”). The mixture of an organic solvent and water includes, for example, a mixture of 1-propanol, methanol, ethanol, 2-propanol, acetone, dimethylsulfoxide, or N,N-dimethylacetamide, and water. The preferable mixture is a mixture of ethanol and water (optionally referred to as “water-containing ethanol”).
- The organic solvent in the mixture of an organic solvent and water may be contained in the range of 0% to 100% as long as the organic solvent and water can be homogeneously mixed, for example, in 30% to 95%, preferably 40% to 90%, more preferably 50% to 90%, and even more preferably 60% to 80%. It is especially preferred that the mixture is 70% water-containing ethanol. Preferably, the organic solvent is contained in about 50 to about 90% per the whole volume of the composition. The temperature in this step is about 1 to about 90° C., preferably about 5 to about 60° C.
- A water solution comprising a surfactant and a buffer is prepared to give a crystallizing agent. The water solution (crystallizing agent) is sterilely filtered through a sterile filter to give a sterile crystallizing agent, and then the agent is sterilely put into a vessel for crystallization whose inside is sterilized (hereinafter, optionally referred to as a “sealed-type vessel for crystalline” or a “sealed vessel”).
- The surfactant includes, for example,
polysorbate 80,polysorbate 20, polyoxyethylene hydrogenatedcastor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188, polyoxyethylene castor oil, benzalkonium chloride, and sodium lauryl sulfate. Two or more of the surfactants may be used. The surfactant may be added to the water solution (i.e. crystallizing agent) and/or the sterile solution prepared in step (1) (i.e. sterile solution of the active ingredient). Preferably, the surfactant ispolysorbate 80. Preferably, the surfactant is contained in about 0.005% (w/v) to about 10% (w/v). The buffer includes, for example, sodium phosphate, sodium dihydrogenphosphate, disodium hydrogenphosphate, potassium dihydrogenphosphate, dipotassium hydrogenphosphate, sodium carbonate, triethanolamine, arginine, and meglumine. Two or more of the buffers may be used. Preferably, the buffer is sodium dihydrogenphosphate or disodium hydrogenphosphate. Preferably, the buffer is contained in about 0.01% (w/v) to about 8% (w/v). The pH of the water solution is about 5 to about 12, and preferably about 7 to about 10. The temperature in this step is about 1 to about 90° C., and preferably about 5 to about 80° C. - The sealed vessel used in this step includes, for example, a vessel made of stainless (e.g. SUS304, SUS316, SUS316L) which is equipped with pipe arrangement, ferrule, valve, jacket, air filter, stirring system, etc. The stirring system includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings), a homomixer, a static mixer and a stirring bar for a magnetic stirrer.
- The sterile solution prepared in step (1) (sterile solution of the active ingredient) is sterilely dropped into the vessel for crystallization (sealed vessel) containing the water solution prepared in step (2) (crystallizing agent). The volume ratio between the solutions of step (2) and step (1) (i.e. volume ratio between the crystallizing agent and the solution of the active ingredient) is about 1:0.1 to about 1:10, preferably about 1:0.2 to about 1:2.
- The present compound is crystallized in this step. The precipitated crystal is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2. The mean particle size of the crystal can be controlled by adjusting the crystallizing temperature, stirring speed, dropping rate, etc., or by adjusting the circulation velocity when using a bypass pathway mentioned below. The crystallizing temperature is preferably about 1 to about 90° C., and more preferably about 5 to about 60° C. The stirring speed is preferably about 50 rpm to about 10000 rpm, more preferably 100 rpm to about 5000 rpm, even more preferably about 100 rpm to about 2000 rpm, and the most preferably about 300 rpm to about 1500 rpm. The dropping rate is calculated by dividing the total volume of the sterile solution of step (1) (i.e. sterile solution of the active ingredient) to be added in Step (3) by the desired time. The dropping rate is, when the total dropped volume of the solution of the active ingredient is n L, preferably about n×0.01 L/min. to n×1 L/min, more preferably about n×0.01 L/min to about n×0.2 L/min, and even more preferably about n×0.05 L/min to about n×0.2 L/min. In more detail, for example, when the total dropped volume of the solution of the active ingredient is 1 L, the dropping rate is about 0.01 L/min to 1 L/min, preferably about 0.01 L/min to about 0.2 L/min, more preferably about 0.05 L/min to about 0.2 L/min; and when the total dropped volume of the solution of the active ingredient is 100 L, the dropping rate is about 1 L/min to 100 L/min, preferably about 1 L/min to about 20 L/min, more preferably about 5 L/min to about 20 L/min. And, when the total dropped volume of the solution of the active ingredient is 1000 L, the dropping rate is about 10 L/min to 1000 L/min, preferably about 10 L/min to about 200 L/min, more preferably about 50 L/min to about 200 L/min.
- In the step (crystallizing step), the sterile solution (sterile solution of the active ingredient) prepared in step (1) can be sterilely added dropwise thereto and simultaneously circulating the solution in the vessel for crystallization via a sealed bypass pathway. Preferably, the bypass pathway has a pump which can pressure a solution in the pathway. Such pump which can pressure a solution includes, for example, a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump), preferably a roller pump.
- The circulation velocity in the bypass pathway is preferably about n×0.001 L/min to about n×2 L/min, more preferably about n×0.01 L/min to about n×1 L/min wherein “n” denotes the total volume of the crystallizing agent and the solution of the active ingredient. In more detail, the circulation velocity is about 1 mL/min to about 2000 mL/min, preferably about 10 mL/min to about 1000 mL/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1 L; about 100 mL/min to about 200 L/min, preferably about 1 L/min to about 100 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 100 L; and about 1 L/min to about 2000 L/min, preferably about 10 L/min to about 1000 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1000 L.
- The crystal precipitated in step (3) is collected through a filter in the sealed vessel. The crystal produced under the condition of in step (3) such as crystallizing temperature and stirring speed has uniform mean particle sizes. The method therefore can prepare a crystal having uniform mean particle sizes without any milling steps. The sealed vessel used in this step includes, for example, a pressurized vessel made of stainless (e.g. SUS304, SUS316, SUS316L) which is equipped with pipe arrangement, ferrule, valve, crystal collection filter, jacket, air filter, stirring system, etc. The stirring system includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings) and a stirring bar for a magnetic stirrer.
- A water solution (vehicle solution) comprising a surfactant (about 0.005 to about 2% (w/v) per the whole of the final formulation), a buffer (about 0.01 to about 2% (w/v) per the whole of the final formulation), an isotonic agent (about 0.1 to about 10% (w/v) per the whole of the final formulation), and water for injection is prepared. The vehicle solution may further comprise a pH regulator, a soothing agent, a polymer, etc. The prepared solution is sterilely filtered through a sterile filter. The resulting vehicle solution is sterilely put into the sealed vessel of step (4) to wash the crystal in the vessel. The washing process may be repeated several times. After washing the crystal, the vehicle solution can be sterilely put into the sealed vessel again and mixed with the crystal to provide a suspension formulation which is the formulation of the invention. In addition, the sterile active ingredient prepared in step (4) may be continuously suspended in the vehicle solution to provide an injectable product (suspension formulation), and furthermore, the active ingredient obtained from the crystallization may be washed with water, an organic solvent or a mixture thereof any of which are sterilely filtered through a sterile filter, and then dried for a while and suspended in the vehicle solution again to prepare a suspension formulation.
- The suspension formulation prepared in Step (5) can be formed as a prefilled formulation through the following step (6).
- The suspension formulation prepared in Step (5) is sterilely put into a container for formulation such as a prefilled syringe, a vial, an ampule, a bag or a Blow-Fill-Seal container. The preferred container includes a prefilled syringe and a vial.
- All of Steps (1) to (6) in the Preparation Method A mentioned above can be continuously carried out under sterile conditions without taking out the crystal during the process. According to the present process, it is possible to easily prepare a sustained release formulation for injection without using the steps of gas sterilization, gamma-ray sterilization, or electron beam sterilization, which is a sterile and dust-free formulation. In addition, the present process provides a sustained-release sterile formulation for injection wherein the active ingredient is uniformly suspended in the solvent.
- Preparation Method A can be partially modified as follows. In the following Preparation Method B, the suspension formulation prepared via Step (1) to Step (5) or Step (6) is not necessarily ensured about sterility. In the following Preparation Method B, the embodiments or preferable embodiments of a surfactant, water, an organic solvent, a mixed solvent of an organic solvent and water, a buffer, an isotonic agent, a bypass pathway, a formulation container, etc. used herein can be the same as Preparation Method A, unless otherwise indicated. In addition, pH, temperature, liquid volume ratio, stirring speed, dropping speed, circulation velocity, etc. used herein are also the same as Preparation Method A, unless otherwise indicated.
- The present compound is dissolved in water, an organic solvent or a mixture thereof with a surfactant to prepare a solution of the active ingredient.
- A water solution comprising a surfactant and a buffer is prepared to give a crystallizing agent. The crystallizing agent is injected into a vessel for crystallization.
- The vessel for crystallization used herein is equipped with a stirring system, whose internal capacity is big enough to contain a solution of the active ingredient and the crystallizing agent. The material of the vessel for crystallization includes a stainless vessel (e.g. SUS304, SUS316, SUS316L). The stirring system set in the vessel for crystallization includes, for example, a part of any stirring system selected from stirring wings (e.g. paddle wings, turbine wings, propeller wings, Pfaudler wings, bar wings, anchor wings), a homomixer, a static mixer and a stirring bar for a magnetic stirrer.
- The solution of the active ingredient prepared in step (1) is dropped into the vessel for crystallization containing the water solution prepared in step (2) (crystallizing agent). The volume ratio between the crystallizing agent and the solution of the active ingredient is about 1:0.1 to about 1:10, preferably about 1:0.2 to about 1:2.
- The present compound is crystallized in this step. The precipitated crystal is a cubic crystal wherein the ratio between length and width of the cubic crystal is about 1:1, and the ratio between length and height thereof is about 1:0.8 to about 1:1.2. The mean particle size of the crystal can be controlled by adjusting the crystallizing temperature, stirring speed, dropping rate, etc., or by adjusting the circulation velocity when using the bypass pathway mentioned below.
- In the step (crystallizing step), the solution of the active ingredient prepared in step (1) can be added dropwise thereto and simultaneously circulating the solution in the vessel for crystallization via a bypass pathway. Preferably, the bypass pathway has a pump which can pressure a solution in the pathway. Such pump which can pressure a solution includes, for example, a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump), preferably a roller pump. Namely, one embodiment of the device which can be used in the crystallizing process of the present invention includes a device equipped with (1) a vessel for crystallization which has a stirring part and can contain a solution of the active ingredient and a crystallizing agent, (2) a bypass pathway connected to the vessel for crystallization which can make a solution in the vessel for crystallization circulated, and (3) a pump set in the bypass pathway which can pressure the solution. In such device, the bypass pathway can connect, for example, from the vessel for crystallization to the pump, and from the pump to the vessel for crystallization, with tube, pipe, etc. The tube includes, for example, but not limited to, silicone tube, flexible polyvinyl chloride tube, polyurethane tube, fluoro-rubber tube, and olefinic tube, and preferably silicone tube.
- The circulation velocity in the bypass pathway is preferably about n×0.001 L/min to about n×2 L/min, more preferably about n×0.01 L/min to about n×1 L/min wherein “n” denotes the total volume of the crystallizing agent and the solution of the active ingredient. In more detail, the circulation velocity is about 1 mL/min to about 2000 mL/min, preferably about 10 mL/min to about 1000 mL/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1 L; about 100 mL/min to about 200 L/min, preferably about 1 L/min to about 100 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 100 L; and about 1 L/min to about 2000 L/min, preferably about 10 L/min to about 1000 L/min when the total volume of the crystallizing agent and the solution of the active ingredient is 1000 L.
- The crystal precipitated in step (3) is collected through a filter. The crystal produced under the condition of in step (3) such as crystallizing temperature, circulation velocity and stirring speed has almost uniform mean particle sizes. The method therefore can prepare a crystal having uniform mean particle sizes without any milling steps.
- A water solution (vehicle solution) comprising a surfactant, a buffer, an isotonic agent, and water for injection is prepared. The vehicle solution may further comprise a pH regulator, a soothing agent, a water-soluble polymer, and other polymers, etc. With the resulting vehicle solution, the crystal of step (4) is washed. The washing process may be repeated several times. After washing the crystal, the vehicle solution can be put into the vessel again and mixed with the crystal to provide a suspension formulation which is the formulation of the invention. In addition, the active ingredient prepared in step (4) may be continuously suspended in the vehicle solution to provide an injectable product (suspension formulation), and additionally, the active ingredient obtained from the crystallization may be washed with water, an organic solvent or a mixture thereof, and then dried for a while and suspended in the vehicle solution again to prepare a suspension formulation.
- The suspension formulation prepared in Step (5) can be formed as a prefilled formulation through the following step (6).
- The suspension formulation prepared in Step (5) is put into a container for formulation such as a prefilled syringe, a vial, an ampule, a bag or a Blow-Fill-Seal container. The preferred container includes a prefilled syringe and a vial.
- The prefilled formulation of the suspension (i.e. container filled with the suspension) prepared in step (6) is sterilized by a process of steaming under pressure. The process can make the level of sterile assurance enhanced.
- The temperature of the steam sterilization under pressure (high-pressure steam sterilization) is preferably 100-150° C., more preferably 115-141° C., and even more preferably 115-126° C. The time for the steam sterilization under pressure can be suitably decided, for example, 1-120 min, more preferably 5-60 min, even more preferably 10-40 min.
- The prefilled formulation of the suspension (i.e. container filled with the suspension) prepared in step (6) or (7) is ultrasonicated. The process can make the uniformity enhanced to enhance the re-suspensiblility when used.
- The frequency of the ultrasonication is preferably 10-200 kHz, more preferably 20-100 kHz, and even more preferably 25-80 kHz. The time for the ultrasonication can be suitably decided, for example, 0.1-120 min, more preferably 0.1-60 min, even more preferably 0.1-30 min.
- It is possible to do any one of the above steps (7) and (8) or both as needed. When step (7) is carried out, it is preferred to do step (8) to uniform the suspension since the active ingredient (free form of Compound 1) contains macroaggregated particles generated due to secondary aggregation (see, for example, Example A2,
FIGS. 4 and 5 mentioned below). - Steps (1)-(6) defined in Preparation Method A are carried out and further any one or both of Step (7) and (8) defined in Preparation Method B are carried out.
- According to the above Preparation Method B′ comprising Step (7), the level for aseptic assurance of the final product can be ensured since Steps (1)-(6) are aseptically carried out, and further the product prepared in Steps (1)-(6) is sterilized by a process of steaming under pressure in Step (7).
- In addition, it is also possible to prepare a similar sustained release formulation for injection from a physically-milled or spray-dried material of the present compound by means of step (5). Furthermore, the aseptic level of the formulation can be enhanced by carrying out Steps (6), (7) and (8).
- Tables 1 and 2 show some typical examples of the sustained release formulation for injection. The examples listed in Tables 1 and 2 including examples which have combinations of the amount of each ingredient are preferable, but the scope of the present invention is not limited thereto.
-
TABLE 1 Ingredients 200 mg/mL 300 mg/mL 400 mg/mL 600 mg/mL Active ingredient 200 mg 300 mg 400 mg 600 mg (free form of Compound 1) Polysorbate 80 1.7 mg 1.5 mg 1.3 mg 0.9 mg Sodium 1.2 mg 1.0 mg 0.9 mg 0.6 mg dihydrogenphosphate(dihydrate) Disodium 2.2 mg 1.9 mg 1.7 mg 1.2 mg hydrogenphosphate(anhydride) Sodium chloride 5.8 mg 5.2 mg 4.6 mg 3.2 mg Water for injection 1 mL (total volume) pH 7 Osmotic pressure ratio 1 Mean particle size 5-25 μm, more preferably 5-20 μm -
TABLE 2 Ingredients 50 mg/mL 100 mg/mL 150 mg/mL Active ingredient 50 mg 100 mg 150 mg (free form of Compound 1) Polysorbate 80 2.0 mg 1.9 mg 1.8 mg Sodium 1.4 mg 1.3 mg 1.2 mg dihydrogenphosphate(dihydrate) Disodium 2.6 mg 2.4 mg 2.3 mg hydrogenphosphate(anhydride) Sodium chloride 6.9 mg 6.5 mg 6.2 mg Water for injection 1 mL (total volume) pH 7 Osmotic pressure ratio 1 Mean particle size 5-25 μm - The present invention is illustrated in more detail by the following examples, but it should not be construed to be limited thereto.
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide hydrochloride (Compound 1) was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 60 (model: MPGL06GH2, pore diameter=0.22 μm, MILLIPORE) to prepare 5200 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm, MILLIPORE) to prepare 5200 g of a crystallizing agent. - To a 1 L glass vessel [model: GLS-80 DURAN™, SCHOTT; with a teflon stirring bar (p 15 mm×70 mm)], 500 g of the crystallizing agent was sterilely injected. Then, maintaining the sealed state of the vessel at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise to the glass vessel at a flow rate of 50 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 750 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The crystal slurry was injected to a pressurized filter system (SUS316; model: SF-145, ADVANTEC) under the sealed state to be filtered through a supported PTFE membrane filter pre-attached to the filter system (model: 13110014, pore diameter=1 μm, ADVANTEC), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- To the crystal of the active ingredient which was collected on the filter, a vehicle solution (about pH 7) comprising sterilely-filtered 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v)
polysorbate 80 was sterilely injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. The injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1. - According to substantially the same procedure as described in Example 1 [Steps (3) to (5)] except that the stirring speed of the magnetic stirrer was 675 rpm, using 500 g of the crystallizing agent and 500 mL of the solution of the active ingredient which were prepared in Example 1, 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared. The injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1.
- According to substantially the same procedure as described in Example 1 [Steps (3) to (5)] except that the stirring speed of the magnetic stirrer was 400 rpm, using 500 g of the crystallizing agent and 500 mL of the solution of the active ingredient which were prepared in Example 1, 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared. The injection volume of the vehicle solution was decided according to “400 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 400 mg/mL sustained-release formulation for injection defined in Table 1.
- Table 3 shows the formulation compositions of Formulations No. 1 to No. 3 which were respectively prepared in Examples 1 to 3.
-
TABLE 3 Formulation composition Active ingredient 400 mg (free form of Compound 1) Polysorbate 80 1.3 mg Sodium dihydrogenphosphate dihydrate 0.9 mg Disodium hydrogenphosphate anhydride 1.7 mg Sodium chloride 4.6 mg Water for injection 1 mL (total volume) - The particle size distribution was determined as a volume basis with a laser diffraction particle size analyzer (model: SALD-3000, Shimadzu Corporation) by wet method using water as a dispersion medium (refractive index: 2.40-0.20 i). The resulting particle size was expressed as a mean particle size (D50) based on its median diameter.
- Table 4 shows the particle size distributions (D10, D50, D90) of Formulations No. 1 to No. 3. These results indicate that it is possible to control the mean particle size of the crystalline active ingredient by changing the stirring speed of the magnetic stirrer, unless the crystallizing temperature, and the fluid volumes of the crystallizing agent and the solution of the active ingredient are varied.
-
TABLE 4 Stirring Particle size distribution (μm) Formulation speed Mean particle size No. (rpm) D10 D50 D90 1 750 5.4 11.1 19.5 2 675 8.1 15.2 21.1 3 400 15.0 19.9 25.1 - To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 5200 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 5000 g of a crystallizing agent. - To a 10 L glass vessel [φ 220 mm×430 mm, caliber φ 95 mm, IWAKI; with a teflon stirring bar for magnetic stirrer (φ 27 mm×108 mm)] whose inside is sterilized, 5000 g of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise to the glass vessel at a flow rate of 500 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 650 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form of
Compound 1. - According to substantially the same procedure as described in Example 1 [Step (5)], adjusting the concentration of the active ingredient by changing the injection volume of the vehicle solution, 300 mg/mL sustained-release formulation for injection defined in Table 1 was prepared.
- The particle size distributions were 5.6 μm (D10), 7.6 μm (mean particle size D50), and 11.7 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 100 (model: MPGL1GCA3, pore diameter=0.22 μm, MILLIPORE) to prepare 5200 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through Millipak™ 100 (pore diameter=0.22 μm) to prepare 5200 g of a crystallizing agent. - To a 1 L glass bottle [model: GLS-80 DURAN™, SCHOTT; with a teflon stirring bar (φ 15 mm×70 mm)] whose inside is sterilized, 600 g of the crystallizing agent was sterilely injected. Then, at a crystallizing temperature of around 1° C. (in ice bath), the solution of the active ingredient was added dropwise to the glass bottle at a flow rate of 60 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 500 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form of
Compound 1. - According to substantially the same procedure as described in Example 1 [Step (5)], adjusting the concentration of the active ingredient by changing the injection volume of the vehicle solution, 200 mg/mL (Formulation No. 4) and 400 mg/mL (Formulation No. 7) sustained-release formulations for injection defined in Table 1 were prepared.
- Into a 10 L glass bottle (φ 220 mm×430 mm, caliber φ 95 mm, IWAKI) whose inside is sterilized, stirring wings (diameter=70 mm, 4 inclined wings, material=SUS304) were sterilely set. Then, under a sterile condition, the crystallizing agent (2500 g) and the solution of the active ingredient (2500 mL) which were prepared in Example 6 were continuously added at a flow rate of 300 mL/min while mixing them with a Y shaped tube (full length=60 mm, internal diameter=6 mm) to the glass bottle wherein the crystallizing temperature was controlled at 25° C. At the time that about 1 L of the mixture was added thereto (i.e. when the stirring wings started to soak the mixture), the stirring at 200 rpm was started with a stirring machine (model: STIRRER SSR, IWAKI). After all of the crystallizing agent and the solution of the active ingredient were added while mixing continuously, the reaction was stirred for another about 15 minutes to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - Similarly, according to the same procedure as described in Example 1 [Step (5)], 200 mg/mL (Formulation No. 5) and 400 mg/mL (Formulation No. 8) sustained-release formulations for injection in Table 1 were prepared by adjusting the volume of the vehicle solution so that the concentration of the active ingredient could be adapted for the desired value.
- To a 2 L glass bottle [model: GLS-80 DURAN™, SCHOTT; with a teflon stirring bar (cp 15 mm×70 mm)] whose inside is sterilized, 1100 g of the crystallizing agent prepared in Example 6 was sterilely injected. Then, the solution of the active ingredient prepared in Example 7 was sterilely added dropwise at a flow rate of 110 mL/min for 10 minutes to the glass bottle wherein the crystallizing temperature was controlled at 40° C. while stirring with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 600 rpm to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - According to substantially the same procedure as described in Example 1 [Step (5)], adjusting the concentration of the active ingredient by changing the injection volume of the vehicle solution, the 200 mg/mL sustained-release formulation for injection defined in Table 1 was prepared.
- To a 1 L glass bottle [model: GLS-80 DURAN™, SCHOTT; with a teflon stirring bar (φ 15 mm×70 mm)] whose inside is sterilized, 400 g of the crystallizing agent prepared in Example 6 was sterilely injected. Then, the solution of the active ingredient prepared in Example 6 was sterilely added dropwise at a flow rate of 40 mL/min for 10 minutes to the glass bottle wherein the crystallizing temperature was controlled at 50° C. while stirring with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 400 rpm to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - According to substantially the same procedure as described in Example 1 [Step (5)], adjusting the concentration of the active ingredient by changing the injection volume of the vehicle solution, the 400 mg/mL sustained-release formulation for injection defined in Table 1 was prepared.
- The free form of
Compound 1 was milled with a Pin Mill (model AVIS-100, DALTON) at a blade rotational speed of 14000 rpm to give a milled active ingredient. To the milled active ingredient, the sterilely-filtered vehicle solution was sterilely injected and the mixture was re-suspended, and then the concentration of the active ingredient was adjusted by changing the injection volume of the vehicle solution to give the 400 mg/mL sustained-release formulation for injection defined in Table 1. - To a 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through SFCA Bottle Top Filter™ [a bottle-top filter system with cellulose acetate membrane, model: 291-4520, pore diameter=0.22 μm, Nalge Nunc International] to prepare 5000 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through SFCA Bottle Top Filter™ [pore diameter=0.22 μm] to prepare 5000 g of a crystallizing agent. - To a 300 mL tall beaker [model: TE-32, IWAKI; with a teflon stirring bar (φ 10 mm×35 mm)], 100 mL of the crystallizing agent was injected. Then, the solution of the active ingredient was added dropwise to the beaker at a flow rate of 10 mL/min for 10 minutes while controlling the crystallizing temperature at 80° C. and stirring with a magnetic stirrer (model: BS-56L-1, IWAKI) at a stirring speed of 1200 rpm to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - According to substantially the same procedure as described in Example 1 [Steps (4) to (5)], adjusting the concentration of the active ingredient by changing the injection volume of the vehicle solution, the 400 mg/mL sustained-release sterile formulation defined in Table 1 was prepared, which is also the same as the formulation defined in Table 3.
- The particle size distribution was 20.8 μm (D10), 54.3 μm (mean particle size D50), and 130.3 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- The sterile formulation of the present invention can be prepared through the non-sterile process of any one of Examples 1 to 11, and then steam sterilization under pressure and ultrasonication (according to, for example, the method of Example A1, B3 or B4).
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 10500 mL of a solution of the active ingredient. Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)polysorbate 80 was filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 10500 g of a crystallizing agent. - To a 10 L glass vessel [φ 220 mm×430 mm, caliber φ 95 mm, IWAKI; with a teflon stirring bar ((27 mm×108 mm)] whose inside is sterilized, 5000 g of the above crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise to the glass vessel at a flow rate of 500 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model: BS-190N, IWAKI) at a stirring speed of 650 rpm to give a crystal slurry of the active ingredient. Using the above 10 L glass vessel, the above procedure was repeated twice to obtain the crystal slurry of the active ingredient whose total amount was 20 L. The crystal in the slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The crystal slurry was injected to a pressurized filter system (model: SF-145, material=SUS316, ADVANTEC) to be filtered through a supported PTFE membrane filter pre-attached to the filter system (model: 13110014, pore diameter=1 μm, ADVANTEC), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- To the crystal of the active ingredient which was collected on the filter, a vehicle solution (about pH 7) comprising sterilely-filtered 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v)
polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. The injection volume of the vehicle solution was decided according to Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 100, 150 and 200 mg/mL sustained-release formulation for injection defined in Table 1. - Each 2 mL of the sustained release formulations for injection wherein the concentrations of the active ingredient are 100, 150, and 200 mg/mL were put into each 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vials were sealed with a rubber stopper and a cap. One mL prefilled syringe (model: V-OVS System 10.6
rubber formulation 40, VETTER) was filled with 1 mL of the sustained release formulation for injection wherein the concentration of the active ingredient is 150 mg/mL and sealed with a rubber stopper (ST-W 1 mL, VETTER). The vials and the prefilled syringe were sterilized at 121° C. for 20 min with a high-pressure steam sterilizer (model: HG-80, HIRAYAMA). Then, the vials and the prefilled syringe were treated for 3 min with an ultrasonicator (model: UT-605HS, SHARP) at 35 kHz. - The particle size distribution was 5.6 μm (D10), 10.3 μm (mean particle size D50) and 16.9 μm (D90) in 100 mg/mL formulation laded in vial; 5.6 μm (D10), 8.6 μm (mean particle size D50) and 13.1 μm (D90) in 150 mg/mL formulation laded in vial; 5.7 μm (D10), 8.7 μm (mean particle size D50) and 13.9 μm(D90) in 200 mg/mL formulation laded in vial; and 9.9 μm (D10), 22.1 μm (mean particle size D50) and 43.2 μm (D90) in 150 mg/mL formulation laded in prefilled syringe, which were determined by using the method measuring particle size distributions defined in Example 4.
- Using the sustained release formulation for injection (in vial) comprising 150 mg/mL crystalline active ingredient which was just sterilized with a high-pressure steam sterilizer in Example A1, (i) non-ultrasonicated formulation (
FIG. 4 ), and (ii) ultrasonicated formulation (35 kHz, 3 min) (FIG. 5 ) were stirred for 30 sec with a vortex mixer (model: MT-51, Yamato), and transferred each to 35 mm polystyrene plate (model: 1000-035, IWAKI). The formulations were observed with the naked eye if they contain macroaggregated particles. - The results showed that there were many secondarily-aggregated macroaggregated particles in (i) non-ultrasonicated formulation as shown in
FIG. 4 , while there were no secondarily-aggregated macroaggregated particles in (ii) ultrasonicated formulation (35 kHz, 3 min). Thus, like the ultrasonicated formulation, it became possible to prepare a sustained release formulation for injection which has uniform crystal of an active ingredient. - Using the sustained release formulation for injection (in vial) comprising 150 mg/mL crystalline active ingredient which was prepared in Example A1, the powder X-ray diffraction was measured (i) before the steam sterilization under pressure, and (ii) after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min).
- The measurement of powder X-ray diffraction was carried out with an X-ray diffraction measurement device [model: X'pert Pro, CuKα source (λ=1.54056 Å), Kevex solid phase Si(Li) ditector, Spectris], The condition of the measurement was Start angle: 5.0°, End angle: 40.00, Step size: 0.017°, Time per step: 5.1 sec, Scan speed: 0.420/sec, X-ray: 45 kV, 40 mA, slit (FDS, FASS): ½, 1, mask: 15. The crystal of the active ingredient was washed with water for injection (Otsuka Parmaceutical) and dried in air overnight. The resulting dried crystal powder was put on the top of a sample holder and the surface thereof was smoothed with a glass slide.
- In the sustained release formulation for injection comprising 150 mg/mL crystalline active ingredient, the result of X-ray diffraction in the sample before the steam sterilization under pressure is shown in Table 5 and
FIG. 6 , and the result of X-ray diffraction in the sample after the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min) is shown in Table 6 andFIG. 7 . - There was no substantial change in the powder X-ray diffraction between the samples before the steam sterilization under pressure and after the steam sterilization under pressure and the ultrasonication.
-
TABLE 5 (before the steam sterilization under pressure) Relative d-spacing Intensity No. 2θ [°] [A] [%] 3 11.2 7.87 38.9 6 14.0 6.33 18.4 7 15.1 5.86 100.0 8 15.6 5.69 90.3 9 16.3 5.44 73.7 10 16.6 5.34 61.1 12 18.1 4.91 86.9 13 19.2 4.63 47.5 14 19.5 4.55 37.7 15 20.0 4.44 98.2 16 20.2 4.40 27.3 17 20.7 4.29 23.8 18 20.9 4.25 33.0 19 22.3 3.98 28.7 22 23.9 3.72 12.1 23 24.2 3.68 19.7 24 24.7 3.61 17.2 25 24.9 3.58 11.3 26 25.4 3.51 25.3 28 26.1 3.42 30.3 29 26.8 3.33 13.7 -
TABLE 6 [After the steam sterilization under pressure (121° C., 20 min) and the ultrasonication (35 kHz, 3 min)] Relative d-spacing Intensity No. 2θ [°] [A] [%] 3 11.2 7.91 36.46 6 13.9 6.35 18.06 7 15.1 5.88 100.00 8 15.5 5.70 90.50 9 16.3 5.46 73.50 10 16.6 5.35 61.58 12 18.0 4.92 84.94 13 19.1 4.64 44.32 14 19.5 4.56 38.45 15 20.0 4.45 96.31 16 20.2 4.40 24.46 17 20.7 4.30 19.77 18 20.9 4.26 34.27 19 22.3 3.99 29.46 21 23.9 3.72 10.77 22 24.1 3.69 21.13 23 24.6 3.61 17.81 24 24.9 3.58 11.59 25 25.3 3.52 26.46 27 26.0 3.42 30.81 28 26.8 3.33 11.85 - Based on the results of powder X-ray diffraction after the steam sterilization under pressure and the ultrasonication (Table 6 and
FIG. 7 ), the specified main and characteristic diffraction peaks are listed below. The values of diffraction peaks at diffraction angle 2θ (°) can include a little measurement errors according to a measurement device or a measurement condition. For example, the measurement error may be ±0.2, preferably ±0.1. - Main diffraction peaks: 2θ (°)=11.2, 15.1, 15.5, 16.3, 16.6, 18.0, 19.1, 19.5, 20.0, 20.9, 22.3, 26.0.
- Characteristic diffraction peaks: 2θ (°)=15.1, 15.5, 16.3, 16.6, 18.0, 20.0.
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 10 L of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 10 kg of a crystallizing agent. - Into a 1 L glass separable flask (φ 110 mm×180 mm), stirring wings (diameter=70 mm, 4 wings whose inclination is 45°, material=SUS304) were set. The crystallizing agent (500 mL) was injected into the 1 L glass separable flask. Then, the solution of the active ingredient was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 400 rpm with a stirring machine (model: FBL1200, Shinto Scientific) for 25 min to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a mixture of a cubic-shaped crystal and an amorphous form which was a free form of
Compound 1. - Into a 1 L glass separable flask (φ 110 mm×180 mm), stirring wings (diameter=70 mm, 4 inclined wings, material=SUS304) were set, and a bypass pathway composed of silicon tube (model: 96410-15, Cole-Parmer), roller pump (model: 7549-32, Cole-Parmer) and pump head (model: 77201-62, Cole-Parmer) was set.
- The crystallizing agent (500 mL) prepared in Example B1 was injected into the 1 L glass separable flask. Then, the solution of the active ingredient prepared in Example B1 was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 400 rpm with a stirring machine (model: FBL1200, Shinto Scientific) for 25 min and simultaneously circulating the solution for 25 min or more at a circulation velocity of 600 mL/min (roller pump, flow rate: 150 mL/min×4 pump heads, model: 7523-00, Cole-Parmer) via the above bypass pathway to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 100 (pore diameter=0.22 μm) to prepare 15.5 L of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was filtered through Millipak™ 100 (pore diameter=0.22 μm) to prepare 15.5 kg of a crystallizing agent. - Into a 35 L SUS316L vessel (φ 330 mm×550 mm), stirring wings (diameter=120 mm, 3 wings whose inclination is 45°, material=SUS316L, SANKO ASTEC) were set, and a sealed-type bypass pathway composed of silicon tube (model: 96410-15, Cole-Parmer), roller pump (model: 7549-32, Cole-Parmer) and pump head (model: 77201-62, Cole-Parmer) was set. The crystallizing agent (15 kg) was injected into the vessel. Then, maintaining the sealed state of the vessel, the solution of the active ingredient was added dropwise at a flow rate of 600 mL/min to the vessel wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 800 rpm (setting pressure: 0.2 MPa) with a stirring machine with air-motor (model: MRV003A, MAGNEO GIKEN) for 25 min and simultaneously circulating the solution for 25 min or more at a circulation velocity of 5.4 L/min (roller pump, flow rate: 900 mL/min×6 pump heads) via the above bypass pathway to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The substantially same process as Example 1 (Steps 4-5) was done by adjusting the volume of the vehicle solution to adjust the concentration of the active ingredient, to prepare a sustained release formulation for injection which contains each ingredient used in the vehicle solution shown in Table 7 that was calculated based on the density of the formulation and 150 mg/mL crystal of the active ingredient.
- Two mL of the sustained release formulations for injection wherein the concentration of the active ingredient is 150 mg/mL was put into 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vial was sealed with a rubber stopper and a cap. The vial was sterilized at 121° C. for 20 min with a high-pressure steam sterilizer (type: HG-80, HIRAYAMA). Then, the vial was treated for 3 min with an ultrasonicator (model: UT-605HS, SHARP) at 35 kHz.
- The particle size distribution was 12.4 μm (D10), 16.7 μm (mean particle size D50) and 21.9 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
-
TABLE 7 Composition of formulation Active ingredient 150 mg (free form of Compound 1) Polysorbate 80 1.8 mg Sodium dihydrogenphosphate 1.2 mg dihydrate Disodium hydrogenphosphate 2.3 mg anhydride Sodium chloride 6.2 mg Water for injection Total 1 mL - To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 100 (pore diameter=0.22 μm) to prepare 50 L of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was filtered through Millipak™ 100 (pore diameter=0.22 μm) to prepare 50 kg of a crystallizing agent. - Into a 150 L SUS304 vessel (φ 544 mm×630 mm), stirring wings (diameter=120 mm, 3 wings whose inclination is 45°, material=SUS316L, SANKO ASTEC) were set, and a bypass pathway composed of silicon tube (model: 96420-82, Cole-Parmer), roller pump (model: 7549-32, Cole-Parmer) and pump head (model: 77601-10, Cole-Parmer) was set. The crystallizing agent (50 kg) was injected into the vessel. Then, the solution of the active ingredient was added dropwise at a flow rate of 2 L/min to the vessel wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 800 rpm (setting pressure: 0.2 MPa) with a stirring machine with air-motor (model: MRV003A, MAGNEO GIKEN) for 25 min and simultaneously circulating the solution for 25 min or more at a circulation velocity of 9 L/min (roller pump, flow rate: 4.5 L/min×2 pump heads) via the above bypass pathway to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The substantially same process as Example 1 (Steps 4-5) was done by adjusting the volume of the vehicle solution to prepare a sustained release formulation for injection which contains each ingredient used in the vehicle solution shown in Table 7 that was calculated based on the density of the formulation and 150 mg/mL crystal of the active ingredient.
- Two mL of the sustained release formulations for injection wherein the concentration of the active ingredient is 150 mg/mL was put into 4 mL vial (model: V-SC4 mL CS, FUJI GLASS), and the vial was sealed with a rubber stopper and a cap. The vial was sterilized at 121° C. for 20 min with a high-pressure steam sterilizer (type: HG-80, HIRAYAMA). Then, the vial was treated for 3 min with an ultrasonicator (model: UT-605HS, SHARP) at 35 kHz.
- The particle size distribution was 14.3 μm (D10), 17.9 μm (mean particle size D50) and 23.0 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- As mentioned above, the crystallizing process was carried out while circulating the solution via the bypass pathway connected to the vessel for crystallization, and it was possible to reproducibly prepare a cubic crystal thereof with a pump in the bypass pathway such as a roller pump (tube pump, hose pump), a reciprocating pump (piston pump, plunger pump, diaphragm pump), and a rotary pump (gear pump, vane pump, screw pump) even when a large-scale preparation.
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80 as a water-containing alcohol solvent,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the mixture was well stirred to be dissolved as far as possible. Then, the solution was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 1000 mL of a 70% ethanol solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 10 kg of a crystallizing agent. - Into a 1 L glass separable flask (p 110 mm×180 mm), stirring wings (diameter=70 mm, 4 inclined wings, material=SUS304) were set, and a bypass pathway composed of silicon tube (model: 96410-15, Cole-Parmer), roller pump (model: 7549-32, Cole-Parmer) and pump head (model: 77201-62, Cole-Parmer) was set. The crystallizing agent (500 mL) was injected into the 1 L glass separable flask. Then, the solution of the active ingredient was added dropwise at a flow rate of 20 mL/min to the flask wherein the crystallizing temperature was controlled at around 25° C. while mixing them at 400 rpm with a stirring machine (model: FBL1200, Shinto Scientific) for 25 min and simultaneously circulating the solution for 25 min or more at a circulation velocity of 600 mL/min (roller pump, flow rate: 150 mL/min×4 pump heads, model: 7523-00, Cole-Parmer) via the above bypass pathway to give a crystal slurry of the active ingredient. The crystal in the crystal slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The crystal slurry was injected to a pressurized filter system (SUS316; model SF-145, ADVANTEC) to be filtered through a supported PTFE membrane filter pre-attached to the filter system (model: 13110014, pore diameter=1 μm, ADVANTEC), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- Water for injection (Otsuka Pharmaceutical) was injected on the crystal of the active ingredient collected on the filter, the crystal was re-suspended, and then the resulting crystal was collected. The procedure was repeated several times to wash the crystal of the active ingredient. The crystal of the active ingredient collected on the supported PTFE membrane filter was dried at 60° C. for 4 hours, the weight of the crystal was weighed (10.51 g, yield: 97.3% from 10.8 g of the starting material).
- The particle size distribution was 5.5 μm (D10), 10.5 μm (mean particle size D50) and 18.9 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4.
- The substantially same process as Example C1 was done by changing the concentration of ethanol used as a water-containing alcohol solvent from 0% to 100% to prepare a cubic-shaped crystal of the active ingredient. The weight of the resulting the crystal of the active ingredient (dried weight), the yield per 10.8 g of the starting material, and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 8.
-
TABLE 8 Concentration of ethanol in the Weight of the Particle size solution of the precipitated Yield per the Particle size distribution Particle size active crystal starting distribution (D50; mean distribution Example No. ingredient (%) (yield)/g material/% (D10)/μm particle size)/μm (D90)/ μm C2 0 1.48 13.7 0.8 3.5 6.6 C3 10 1.62 15.0 2.3 5.6 10.9 C4 20 2.16 20.0 3.9 8.8 17.9 C5 30 3.42 31.7 3.3 7.4 12.1 C6 40 6.27 58.1 5.6 8.4 13.0 C7 50 9.63 89.2 6.0 8.7 12.7 C8 60 10.38 96.1 5.6 9.4 17.5 C1 70 10.51 97.3 5.5 10.5 18.9 C9 80 10.12 93.7 6.6 13.0 21.1 C10 90 6.03 55.8 5.4 10.9 19.4 C11 100 1.14 10.6 5.0 12.5 24.1 - Based on the above-listed results of each particle size of the prepared cubic crystal and each yield, the content of an organic solvent in the mixture of an organic solvent and water to prepare the solution of the active ingredient was preferably 40 to 90%, more preferably 60 to 80%. In particular, aqueous 70% ethanol solution was the most preferred.
- To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 5200 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 80 was sterilely filtered through Millipak™ 60 (pore diameter=0.22 μm) to prepare 5200 g of a crystallizing agent. - To a 10 L glass vessel [φ 220 mm×430 mm, caliber φ 95 mm, IWAKI; with a teflon stirring bar for magnetic stirrer (φ 27 mm×108 mm)] whose inside is sterilized, 5000 g of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise to the glass vessel at a flow rate of 500 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model BS-190N, IWAKI) at a stirring speed of 600 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form of
Compound 1. - The crystal slurry was injected to a SUS316 pressurized filter system (model SF-145, ADVANTEC) to be filtered through a supported PTFE membrane filter pre-attached to the filter system (model: 13110014, pore diameter=1 μm, ADVANTEC), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- To the crystal of the active ingredient which was collected on the filter, a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.005% (w/v)
polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. The injection volume of the vehicle solution was decided according to “300 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 300 mg/mL sustained-release formulation for injection defined in Table 1. The particle size distribution was 9.0 μm (D10), 18.3 μm (mean particle size D50) and 30.6 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4. - In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 300 mg/mL (50, 100, 150, 200, 250, 400, 500, 600 mg/mL, etc.)[Example D1a].
- The substantially same process as Example D1 was done by using the crystal of the active ingredient prepared in Example D1 and changing the concentration of
polysorbate 80 used in the vehicle solution from 0.01% (w/v) to 0.10% (w/v) to prepare a sustained release formulation for injection which contains 300 mg/mL cubic-shaped crystal of the active ingredient [Examples D2-D5]. The particle size distribution of the resulting formulations which was measured according to the method of Example 4 is shown in Table 9. - Likewise, the substantially same process as Example D1 was done by changing the concentration of
polysorbate 80 used in the vehicle solution from 0.5% (w/v) to 2.0% (w/v) to prepare a sustained release formulation for injection which contains a cubic-shaped crystal of the active ingredient [Examples D6-D9; Table 10]. - In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 300 mg/mL (50, 100, 150, 200, 250, 400, 500, 600 mg/mL, etc.) (Examples D2a-D9a; Table 11).
-
TABLE 9 Concentration of polysorbate 80Concentration of Particle size in the vehicle the active Particle size distribution Particle size solution ingredient distribution (D50; mean distribution Example No. (% (w/v)) (mg/mL) (D10)/μm particle size)/μm (D90)/μm D1 0.005 300 9.0 18.3 30.6 D2 0.01 300 8.4 17.6 29.5 D3 0.02 300 7.3 13.8 23.4 D4 0.05 300 7.5 13.5 20.1 D5 0.10 300 7.2 12.1 20.4 -
TABLE 10 Concentration of polysorbate 80 in theConcentration of the Example vehicle solution active ingredient No. (% (w/v)) (mg/mL) D6 0.5 300 D7 1.0 300 D8 1.5 300 D9 2.0 300 -
TABLE 11 Concentration of polysorbate 80 in theConcentration Example vehicle solution of the active No. (% (w/v)) ingredient (mg/mL) D1a 0.005 50, 100, 150, 200, 250, 400, 500, 600, etc. D2a 0.01 50, 100, 150, 200, 250, 400, 500, 600, etc. D3a 0.02 50, 100, 150, 200, 250, 400, 500, 600, etc. D4a 0.05 50, 100, 150, 200, 250, 400, 500, 600, etc. D5a 0.10 50, 100, 150, 200, 250, 400, 500, 600, etc. D6a 0.5 50, 100, 150, 200, 250, 400, 500, 600, etc. D7a 1.0 50, 100, 150, 200, 250, 400, 500, 600, etc. D8a 1.5 50, 100, 150, 200, 250, 400, 500, 600, etc. D9a 2.0 50, 100, 150, 200, 250, 400, 500, 600, etc. - Step (1): To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 20,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 120 mL of a solution of the active ingredient.
Step (2): Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)polysorbate 20 was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 120 mL of a crystallizing agent.
Step (3): To a 100 mL vial container with a scale attachment [model: WT-110, NICHIDEN-RIKA GLASS; with a teflon stirring bar (φ 8 mm×35 mm)], 50 mL of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise into the glass bottle at a flow rate of 5 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model BS-56L-1, IWAKI) at a stirring speed of 1200 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form ofCompound 1.
Step (4): The crystal slurry was injected to a reduced-pressure-type glass filter system (index No. XX1504700, MILLIPORE) to be filtered through Omnipore™ membrane filter pre-attached to the filter system (model: JAWP, pore diameter=1 μm, MILLIPORE), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
Step (5): To the crystal of the active ingredient which was collected on the filter, a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.20% (w/v)polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. A sustained-release formulation for injection containing 200 mg/mL the active ingredient was prepared by adjusting the volume of the vehicle solution. The particle size distribution was 7.5 μm (D10), 9.8 μm (mean particle size D50) and 13.1 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4. - In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example E1a].
- Furthermore, the
polysorbate 80 contained in the vehicle solution can be replaced withpolysorbate 20 and the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) [Example E1b]. - The surfactant (polysorbate 20) used in the solution of the active ingredient (Step (1)) and the crystallizing agent (Step (2)) in Example E1 were replaced with any other surfactant in the same concentration such as polyoxyethylene hydrogenated castor oil 50 [Example E2], polyoxyethylene hydrogenated castor oil 60 [Example E3], poloxamer 188 [Example E4], polyoxyethylene castor oil [Example E5], benzalkonium chloride [Example E6], sodium lauryl sulfate [Example E7], and additive-free (0%) [Example E8], and then the substantially same process as Example E1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient. The surfactant used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 12.
- In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.)(Table 13).
- In addition, the
polysorbate 80 used in the vehicle solution (Step (5)) in Example E1 was replaced with any other surfactant in the same concentration such as polyoxyethylene hydrogenated castor oil 50 [Example E2b], polyoxyethylene hydrogenated castor oil 60 [Example E3b], poloxamer 188 [Example E4b], polyoxyethylene castor oil [Example E5b], benzalkonium chloride [Example E6b], and sodium lauryl sulfate [Example E7b], and then the substantially same process as Step (5) in Example E1 was done adjusting the volume of the vehicle solution to prepare a formulation which contains a cubic-shaped crystal of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 14). -
TABLE 12 Surfactant in the solution of the active Surfactant in the ingredient and vehicle solution in Concentration of the Particle size crystallizing agent Step (5) active ingredient Particle size distribution (D50; mean Particle size Example No. (each 1%(w/v) (each 0.2% (w/v) (mg/mL) distribution (D10)/μm particle size)/μm distribution (D90)/ μm E1 polysorbate 20 polysorbate 200 7.5 9.8 13.1 80 E2 polyoxyethylene polysorbate 200 11.9 15.1 19.5 hydrogenated 80 castor oil 50E3 polyoxyethylene polysorbate 200 9.8 12.3 15.7 hydrogenated 80 castor oil 60 E4 poloxamer 188 polysorbate 200 8.1 15.1 24.8 80 E5 polyoxyethylene polysorbate 200 7.9 13.7 19.2 castor oil 80 E6 benzalkonium polysorbate 200 9.2 12.9 19.0 chloride 80 E7 sodium lauryl polysorbate 200 10.0 15.3 21.0 sulfate 80 E8 additive-free polysorbate 200 53.1 180.6 284.4 (0%) 80 -
TABLE 13 Surfactant in the solution of Surfactant in the active the vehicle ingredient and solution in Concentration crystallizing Step (5) of the active Example agent (each 1% (each 0.2% ingredient No. (w/v) (w/v) (mg/mL) E1a polysorbate 20 polysorbate 8050, 100, 150, 250, 300, 400, 500, 600, etc. E2a polyoxyethylene polysorbate 80 50, 100, 150, hydrogenated 250, 300, 400, castor oil 50500, 600, etc. E3a polyoxyethylene polysorbate 80 50, 100, 150, hydrogenated 250, 300, 400, castor oil 60 500, 600, etc. E4a poloxamer 188 polysorbate 8050, 100, 150, 250, 300, 400, 500, 600, etc. E5a polyoxyethylene polysorbate 80 50, 100, 150, castor oil 250, 300, 400, 500, 600, etc. E6a benzalkonium polysorbate 8050, 100, 150, chloride 250, 300, 400, 500, 600, etc. E7a sodium lauryl polysorbate 80 50, 100, 150, sulfate 250, 300, 400, 500, 600, etc. -
TABLE 14 Surfactant in the solution of the active Surfactant in ingredient and the vehicle crystallizing solution in Step Concentration of Example agent (each 1% (5) the active No. (w/v) (each 0.2% (w/v) ingredient (mg/mL) E1b polysorbate 20 polysorbate 2050, 100, 150, 200, 250, 300, 400, 500, 600, etc. E2b polyoxyethylene polyoxyethylene 50, 100, 150, 200, hydrogenated hydrogenated 250, 300, 400, castor oil 50castor oil 50500, 600, etc. E3b polyoxyethylene polyoxyethylene 50, 100, 150, 200, hydrogenated hydrogenated 250, 300, 400, castor oil 60 castor oil 60 500, 600, etc. E4b poloxamer 188 poloxamer 188 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. E5b polyoxyethylene polyoxyethylene 50, 100, 150, 200, castor oil castor oil 250, 300, 400, 500, 600, etc. E6b benzalkonium benzalkonium 50, 100, 150, 200, chloride chloride 250, 300, 400, 500, 600, etc. E7b sodium lauryl sodium lauryl 50, 100, 150, 200, sulfate sulfate 250, 300, 400, 500, 600, etc. - To an aqueous 70% ethanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 500 mL of a solution of the active ingredient. - Meanwhile, a water solution of 50 mmol/L dipotassium hydrogenphosphate/1% (w/v)
polysorbate 80 was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 500 g of a crystallizing agent. - To a 100 mL vial container with a scale attachment [model: WT-110, NICHIDEN-RIKA GLASS; with a teflon stirring bar (
φ 8 mm×35 mm)], 50 mL of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise into the glass bottle at a flow rate of 5 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model BS-56L-1, IWAKI) at a stirring speed of 1200 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form ofCompound 1. - The crystal slurry was injected to a reduced-pressure-type glass filter system (index No. XX1504700, MILLIPORE) to be filtered through Omnipore™ membrane filter pre-attached to the filter system (model: JAWP, pore diameter=1 μm, MILLIPORE), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- To the crystal of the active ingredient which was collected on the filter, a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/0.70% (w/v) sodium chloride/0.2% (w/v)
polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. The injection volume of the vehicle solution was decided according to “200 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 200 mg/mL sustained-release formulation for injection defined in Table 1. The particle size distribution was 6.3 μm (D10), 10.2 μm (mean particle size D50), 16.7 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4. - In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example F1a].
- Furthermore, the 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride) contained in the vehicle solution can be replaced with potassium dihydrogenphosphate/dipotassium hydrogen phosphate in order to adjust pH to around 7, and the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) [Example F1b].
- The 50 mmol/L dipotassium hydrogen phosphate (buffer) used in the crystallizing agent in Example F1 was replaced with any other buffer in the same mole concentration (mol/L) or a pH regulator such as arginine [Example F2], trometamol [Example F3], sodium carbonate [Example F4], triethanolamine [Example F5], meglumine [Example F6], sodium hydroxide [Example F7], and disodium hydrogenphosphate [Example F8]) and then the substantially same process as Example F1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient. The buffer used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 15.
- In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.)(Table 16).
- In addition, the buffer [0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)] used in the vehicle solution in Example F1 was replaced with any other buffer such as L-arginine hydrochloride/L-arginine (pH: about 7) [Example F2b], trometamol (pH: about 7) [Example F3b], sodium hydrogen carbonate/sodium carbonate (pH: about 7) [Example F4b], triethanolamine (pH: about 7) [Example F5b], and meglumine (pH: about 7) [Example F6b]), and then the substantially same process as Example F1 was done adjusting the volume of the vehicle solution to prepare a formulation which contains a cubic-shaped crystal of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 17).
-
TABLE 15 Buffer in the Concentration of Particle size crystallizing Buffer in the the active Particle size distribution Particle size agent (each 50 vehicle ingredient distribution (D50; mean distribution Example No. mmol/L) solution (mg/mL) (D10)/μm article size)/μm (D90)/μm F1 dipotassium hydrogen 0.14% (w/v) sodium 200 6.3 10.2 16.7 phosphate dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride) F2 arginine same as above 200 8.1 10.2 13.4 F3 trometamol same as above 200 7.1 10.5 19.4 F4 sodium same as above 200 7.2 9.6 14.8 carbonate F5 triethanol- same as above 200 8.0 10.5 14.8 amine F6 meglumine same as above 200 6.7 9.0 15.8 F7 sodium same as above 200 19.2 25.6 33.4 hydroxide F8 disodium same as above 200 6.3 10.2 16.7 hydrogen- phosphate -
TABLE 16 Buffer in the Concentration crystallizing of the active Example agent Buffer in the ingredient No. (each 50 mmol/L) vehicle solution (mg/mL) F1a dipotassium 0.14% (w/v) sodium 50, 100, 150, hydrogen dihydrogenphosphate 250, 300, 400, phosphate (dihydrate)/0.26% 500, 600, etc. (w/v)disodium hydrogenphosphate (anhydride) F2a arginine same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F3a trometamol same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F4a sodium carbonate same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F5a triethanolamine same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F6a meglumine same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F7a sodium hydroxide same as above 50, 100, 150, 250, 300, 400, 500, 600, etc. F8a disodium same as above 50, 100, 150, hydrogenphosphate 250, 300, 400, 500, 600, etc. -
TABLE 17 Buffer in the crystallizing Concentration of Example agent Buffer in the the active No. (each 50 mmol/L) vehicle solution ingredient (mg/mL) F1b dipotassium potassium 50, 100, 150, 200, hydrogen dihydrogen- 250, 300, 400, phosphate phosphate/ 500, 600, etc. dipotassium hydrogen phosphate (pH about 7) F2b arginine L- arginine 50, 100, 150, 200, hydrochloride/L- 250, 300, 400, arginine 500, 600, etc. (pH about 7) F3b trometamol trometamol 50, 100, 150, 200, (pH about 7) 250, 300, 400, 500, 600, etc. F4b sodium carbonate sodium hydrogen 50, 100, 150, 200, carbonate/sodium 250, 300, 400, carbonate 500, 600, etc. (pH about 7) F5b triethanolamine triethanolamine 50, 100, 150, 200, (pH about 7) 250, 300, 400, 500, 600, etc. F6b meglumine meglumine 50, 100, 150, 200, (pH about 7) 250, 300, 400, 500, 600, etc. - The 0.70% (w/v) sodium chloride (isotonic agent) used in the vehicle solution in Example F1 can be replaced with any other isotonic agent such as D-mannitol [about 5% (w/v); Example F9], D-fructose [about 5% (w/v); Example F10], D-xylitol [about 5% (w/v); Example F11], D-sorbitol [about 5% (w/v); Example F12], D-lactose [about 10% (w/v); Example F13], D-glucose [about 5% (w/v); Example F14], D-trehalose [about 10% (w/v); Example F15], and D-sucrose [about 10% (w/v); Example F16] and D-maltose [about 5% (w/v); Example F17]) to prepare a sustained release formulation for injection of the present invention. The volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 18).
-
TABLE 18 Concentration of Isotonic agent isotonic agent (per Concentration of Example in the vehicle the vehicle the active No. solution solution) % (w/v) ingredient (mg/mL) F1 sodium chloride 0.70 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F9 D-mannitol about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F10 D-fructose about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F11 D-xylitol about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F12 D-sorbitol about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F13 D-lactose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F14 D-glucose about 5 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F15 D-trehalose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F16 D-sucrose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. F17 D-maltose about 10 50, 100, 150, 200, 250, 300, 400, 500, 600, etc. - Lidocaine hydrochloride [about 0.5% (w/v)−2% (w/v)] can be additionally contained in the vehicle solution prepared in Example F8 and the volume of the vehicle solution can be adjusted to prepare a formulation of lidocaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- Lidocaine hydrochloride described in Example F17 can be replaced with procaine hydrochloride [about 0.5% (w/v)-2% (w/v)] and the volume of the vehicle solution can be adjusted to prepare a formulation of procaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- Lidocaine hydrochloride described in Example F17 can be replaced with meprylcaine hydrochloride [about 1% (w/v)-3% (w/v)] and the volume of the vehicle solution can be adjusted to prepare a formulation of meprylcaine hydrochloride in any concentration (50, 100, 150, 200, 250, 300, 400, 500, 600 mg/mL, etc.).
- To an aqueous 70% methanol solution containing 1% (w/v)
polysorbate 80,Compound 1 was dissolved so that the concentration ofCompound 1 should be 2% (w/v), and then the solution was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 120 mL of a solution of the active ingredient. - Meanwhile, a water solution of 0.7% (w/v) disodium hydrogenphosphate (anhydride)/1% (w/v)
polysorbate 20 was sterilely filtered through SFCA Bottle Top Filter™ (pore diameter=0.22 μm) to prepare 120 mL of a crystallizing agent. - To a 100 mL vial container with a scale attachment [model: WT-110, NICHIDEN-RIKA GLASS; with a teflon stirring bar (
φ 8 mm×35 mm)], 50 mL of the crystallizing agent was injected. Then, at a crystallizing temperature of around 25° C., the solution of the active ingredient was added dropwise into the glass bottle at a flow rate of 5 mL/min for 10 minutes while stirring the reaction with a magnetic stirrer (model BS-56L-1, IWAKI) at a stirring speed of 1200 rpm to give a crystal slurry of the active ingredient. The crystal in the slurry was a cubic-shaped crystal which was a free form ofCompound 1. - The crystal slurry was injected to a reduced-pressure-type glass filter system (index No. XX1504700, MILLIPORE) to be filtered through Omnipore™ membrane filter pre-attached to the filter system (model: JAWP, pore diameter=1 μm, MILLIPORE), then the crystal of the active ingredient was collected on the filter, and the liquid ingredients were removed.
- To the crystal of the active ingredient which was collected on the filter, a sterilely-filtered vehicle solution (about pH 7) comprising 0.14% (w/v) sodium dihydrogenphosphate (dihydrate)/0.26% (w/v) disodium hydrogenphosphate (anhydride)/5.0% (w/v) D-mannitol/0.2% (w/v)
polysorbate 80 was injected, and then the mixture was re-suspended, and filtered. After repeating this procedure several times, the vehicle solution was injected thereto again to prepare the desired formulation. The injection volume of the vehicle solution was decided according to “200 mg/mL” in Table 1 so that each ingredient could be adapted to the amount calculated based on its density to prepare 200 mg/mL sustained-release formulation for injection defined in Table 1. The particle size distribution was 5.5 μm (D10), 7.4 μm (mean particle size D50), 9.4 μm (D90), which were determined by using the method measuring particle size distributions defined in Example 4. In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) [Example G1a]. - The methanol used in the solution of the active ingredient in Example G1 was replaced with any other organic solvent such as acetone [Example G2], N,N-dimethylacetamide [Example G3], 1-propanol [Example G4], 2-propanol [Example G5], and dimethylsulfoxide [Example G6]) and then the substantially same process as Example G1 was done to prepare a sustained release formulation for injection which contains 200 mg/mL cubic-shaped crystal of the active ingredient. The solvent used in each example and the particle size distribution of the resulting formulations which was measured according to the method of Example 4 are shown in Table 19.
- In addition, the volume of the vehicle solution can be adjusted to prepare a formulation of the active ingredient in any concentration besides 200 mg/mL (50, 100, 150, 250, 300, 400, 500, 600 mg/mL, etc.) (Table 20).
-
TABLE 19 Organic solvent in the solution of the active ingredient Concentration of the active Particle size distribution Particle size distribution Particle size distribution Example No. (concentration: 70%) ingredient (mg/mL) (D10)/μm (D50; mean particle size)/μm (D90)/μm G1 methanol 200 5.5 7.4 9.4 G2 acetone 200 8.4 15.1 21.4 G3 N,N- 200 4.1 8.8 18.9 dimethyl- acetamide G4 1- 200 10.5 18.4 25.9 propanol G5 2- 200 4.8 10.3 25.2 propanol G6 dimethyl- 200 5.3 10.8 16.9 sulfoxide -
TABLE 20 Organic solvent in the solution of the active ingredient Concentration of the active Example No. (concentration: 70%) ingredient (mg/mL) G1a methanol 50, 100, 150, 250, 300, 400, 500, 600, etc. G2a acetone 50, 100, 150, 250, 300, 400, 500, 600, etc. G3a N,N- dimethylacetamide 50, 100, 150, 250, 300, 400, 500, 600, etc. G4a 1- propanol 50, 100, 150, 250, 300, 400, 500, 600, etc. G5a 2- propanol 50, 100, 150, 250, 300, 400, 500, 600, etc. G6a dimethylsulfoxide 50, 100, 150, 250, 300, 400, 500, 600, etc. - Table 21 shows the formulation composition of Formulations No. 4 to No. 6, wherein all of the formulations have 200 mg/mL of the active ingredient.
- Table 22 shows the obtained particle size distributions (D10, D50, D90) of Formulations No. 4 to 6 which were determined by the measurement method of particle size distribution described in Example 4. The mean particle sizes were 5.0 μm (Formulation No. 4), 11.3 μm (Formulation No. 5), and 25.8 μm (Formulation No. 6).
-
TABLE 21 Formulation composition Active ingredient 200 mg (free form of Compound 1) Polysorbate 80 1.7 mg Sodium dihydrogenphosphate dihydrate 1.2 mg Disodium hydrogenphosphate anhydride 2.2 mg Sodium chloride 5.8 mg Water for injection 1 mL (total volume) -
TABLE 22 Particle size distribution (μm) Formulation Mean particle size Example No. D10 D50 D90 6 4 0.5 5.0 7.9 7 5 6.3 11.3 17.5 8 6 17.5 25.8 35.0 - Each of the formulations having 200 mg/mL of the active ingredient (i.e. Formulations No. 4 to No. 6) was administered to gastrocnemius muscle of six rats [Sprague-Dawley rats (SD), male, 9 weeks old, 250-300 g] in a dose of 50 mg/kg (0.25 mL/kg). The blood was collected 1, 2, and 4 hours, 1, 2, 4, 7, 14, 21, and 28 days after the administration, and the results showed that the blood level of the present compound held up well. As shown in
FIG. 2 , in case that the mean particle size was 5.0 μm (Formulation No. 4), the present compound rapidly disappeared from the blood after 7 days (1 week); whereas in case that the mean particle size was 11.3 μm (Formulation No. 5) and 25.8 μm (Formulation No. 6), the blood level of the present compound held up well for at least 14 days (2 weeks). - Table 23 shows the formulation composition of Formulations No. 7 to No. 10, wherein all of the formulations have 400 mg/mL of the active ingredient.
- Table 24 shows the obtained particle size distributions (D10, D50, D90) of Formulations No. 7 to 10 which were determined by the measurement method of particle size distribution described in Example 4. The mean particle sizes were 4.8 μm (Formulation No. 7), 11.1 μm (Formulation No. 8), 20.0 μm (Formulation No. 9), and 11.7 μm (Formulation No. 10).
-
TABLE 23 Formulation composition Active ingredient 400 mg (free form of Compound 1) Polysorbate 80 1.3 mg Sodium dihydrogenphosphate dihydrate 0.9 mg Disodium hydrogenphosphate anhydride 1.7 mg Sodium chloride 4.6 mg Water for injection 1 mL (total volume) -
TABLE 24 Particle size distribution (μm) Formulation Mean particle size Example No. D10 D50 D90 6 7 0.4 4.8 7.8 7 8 5.9 11.1 17.5 9 9 13.6 20.0 28.2 10 10 0.5 11.7 34.1 - Each of the formulations having 400 mg/mL of the active ingredient (i.e. Formulations No. 7 to No. 10) was administered to gastrocnemius muscle of six rats [Sprague-Dawley rats (SD), male, 9 weeks old, 250-300 g] in a dose of 100 mg/Kg (0.25 mL/kg). The blood was collected 1, 2, and 4 hours, 1, 2, 4, 7, 14, 21, and 28 days after the administration, and the results showed that the blood level of the present compound held up well. As shown in
FIG. 3 , in case that the mean particle size was 4.8 μm (Formulation No. 7), the present compound rapidly disappeared from the blood after 7 days (1 week); whereas in case that the mean particle size was 11.1 μm (Formulation No. 8), 20.0 μm (Formulation No. 9) and 11.7 μm (Formulation No. 10), the blood level of the present compound held up well for at least 14 days (2 weeks). - Each of the active ingredient crystals having the following mean particle size:
- 11.1 μm (Formulation No. 1, prepared in Example 1);
15.2 μm (Formulation No. 2, prepared in Example 2);
19.9 μm (Formulation No. 3, prepared in Example 3); and
54.3 μm (Formulation No. 11, prepared in Example 11) was formulated to three types of formulations having a concentration of 200, 300, and 400 mg/mL. 1 mL of each formulation was put into a 2.5 mL syringe equipped with a 22 gauge needle (the length of the needle=1½, Terumo). As a material for evaluating the needle passability, pork ham and melamine form (AISEN) were selected because these materials are similar to muscles in the point that they require considerable power to insert the needle into the materials. Each formulation was injected into the materials, and then the needle passability was evaluated by judging whether the whole amount of each formulation could be injected or not (i.e. whether the needle's inside is clogged with the crystal or not). The results of pork ham and melamine form are shown in Table 25 and Table 26, respectively. In Table 25 and Table 26, “∘” shows that it was possible to inject the whole amount of the formulation into the materials, whereas “x” shows that it was difficult to inject all of them. As a result, there is no difference between pork ham and melamine form when they are used as a material for evaluating the needle passability, and the results also indicate that it would be more difficult to make an injection with the needle when the active ingredients are more concentrated and the mean particle sizes are bigger. -
TABLE 25 Injection into pork ham Concentration of active Formulation Mean particle ingredient (mg/mL) No. size (μm) 200 300 400 1 11.1 ∘ ∘ ∘ 2 15.2 ∘ ∘ ∘ 3 19.9 ∘ ∘ x 11 54.3 ∘ x x -
TABLE 26 Injection into melamine form Mean particle Concentration of active Formulation size ingredient (mg/mL) No. (μm) 200 300 400 1 11.1 ∘ ∘ ∘ 2 15.2 ∘ ∘ ∘ 3 19.9 ∘ ∘ x 11 54.3 ∘ x x - In order to evaluate the effect of the mean particle size on the needle passability in more detail, formulations of the crystal which have a concentration of 200-400 mg/mL with a 10 mg/mL interval were prepared with the crystals having a mean particle size of 11.1-84.9 μm. 1 mL of each formulation was put into a 2.5 mL syringe equipped with an 18 to 22 gauge needle (the length of the needle=1½, Terumo) or a 23 gauge needle (the length of the needle=1¼, Terumo). Each formulation was injected into the melamine form used in Example 14, and the needle passability was evaluated by judging whether the whole amount of each formulation could be injected or not (i.e. whether the needle's inside is clogged with the crystal or not). Table 27 shows the results of these. In Table 27, “∘” shows that it is possible to inject the whole amount of the formulation into the melamine form, whereas “x” shows that it is difficult to inject them, and also the gauge needle is shown in brackets. The results are as follows:
- (i) when the mean particle size of the crystal was less than 54.3 μm, the formulations at a concentration of less than 220 mg/mL were able to pass through a needle of 23 gauge;
(ii) when the mean particle size of the crystal was less than 25.2 μm, the formulations at a concentration of less than 260 mg/mL were able to pass through at least a needle of 22 gauge;
(iii) when the mean particle size of the crystal was less than 19.9 μm, the formulations at a concentration of less than 300 mg/mL were able to pass through at least a needle of 22 gauge;
(iv) when the mean particle size of the crystal was less than 17.6 μm, the formulations at a concentration of less than 330 mg/mL were able to pass through at least a needle of 22 gauge; and
(v) when the mean particle size of the crystal was less than 15.2 μm, the formulations at a concentration of less than 400 mg/mL were able to pass through at least a needle of 22 gauge. -
TABLE 27 Mean particle Concentrations of active ingredient (mg/mL) size 50- 200- 230- 270- 310- 340- (μm) 190 220 260 300 330 400 11.1 ∘ ∘ ∘ ∘ ∘ ∘ (18- (18- (18- (18- (18- (18- 23G) 23G) 23G) 23G) 23G) 23G) 15.2 ∘ ∘ ∘ ∘ ∘ ∘ (18- (18- (18- (18- (18- (18- 23G) 23G) 23G) 23G) 23G) 22G) 17.6 ∘ ∘ ∘ ∘ ∘ x (18- (18- (18- (18- (18- (18G) 23G) 23G) 23G) 23G) 22G) 19.9 ∘ ∘ ∘ ∘ x x (18- (18- (18- (18- (18G) (18G) 23G) 23G) 23G) 22G) 25.2 ∘ ∘ ∘ x x x (18- (18- (18- (18G) (18G) (18G) 23G) 23G) 22G) 54.3 ∘ ∘ x x x x (18- (18- (18G) (18G) (18G) (18G) 23G) 23G) 56.1 x x x x x x (18G) (18G) (18G) (18G) (18G) (18G) 84.9 x x x x x x (18G) (18G) (18G) (18G) (18G) (18G) - The present invention can get more patients effectively treated because the present compound in the present formulation can be continuously released for at least more than 2 to 4 weeks, and the present compound can be also formulated into a sustained release formulation for injection which has a good needle passability.
Claims (25)
1. (canceled)
2: A sustained release formulation, comprising:
a composition including
N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetra-methylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]heptanedicarboximide as an active ingredient, which is in a form of a crystal having a mean particle size range within from 4 μm to 26 μm, and
a surfactant comprising at least one ingredient selected from the group consisting of polysorbate 80, polysorbate 20, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60, poloxamer 188 and polyoxyethylene castor oil.
3: The sustained release formulation of claim 2 , wherein the mean particle size range is 4 μm-20 μm, 4 μm-18 μm, 4 μm-16 μm, 5 μm-26 μm, 5 μm-20 μm, 5 μm-18 μm, 5 μm-16 μm, 8 μm-20 μm, 10 μm-26 μm, 10 μm-20 μm, 10 μm-18 μm, or 10 μm-16 μm.
4: The sustained release formulation of claim 2 , wherein the crystal is a cubic crystal.
5: The sustained release formulation of claim 4 , wherein the cubic crystal has a length to width ratio of 1:1, and a length to height ratio of 1:0.8 to 1:1.2.
6: The sustained release formulation of claim 2 , wherein the active ingredient in the form of the crystal is included in 5% (w/v) to 60% (w/v) with respect to a total amount of the composition.
7: The sustained release formulation of claim 2 , wherein the surfactant is polysorbate 80.
8: The sustained release formulation of claim 2 , wherein the surfactant is included in a concentration of 0.05 mg/ml to 20 mg/ml.
9: The sustained release formulation of claim 2 , wherein the composition further comprises a buffer.
10: The sustained release formulation of claim 9 , wherein the buffer is at least one ingredient selected from the group consisting of sodium phosphate, disodium hydrogenphosphate, sodium dihydrogenphosphate, potassium phosphate, dipotassium hydrogenphosphate, potassium dihydrogenphosphate, trometamol, sodium carbonate, sodium bicarbonate, meglumine, arginine, triethanolamine and citric acid.
11: The sustained release formulation of claim 9 , wherein the buffer is included in 0.01% (w/v) to 2% (w/v) with respect to a total amount of the composition.
12: The sustained release formulation of claim 2 , wherein the composition further comprises an isotonic agent.
13: The sustained release formulation of claim 12 , wherein the isotonic agent is at least one ingredient selected from the group consisting of sodium chloride and D-mannitol.
14: The sustained release formulation of claim 12 , wherein the isotonic agent is included in 0.1% (w/v) to 10% (w/v) with respect to a total amount of the composition.
15: The sustained release formulation of claim 2 , wherein the composition further comprises water.
16: The sustained release formulation of claim 2 , wherein the active ingredient is included in a concentration of 50 mg/mL to 600 mg/mL.
17: The sustained release formulation of claim 9 , wherein the buffer is included in a concentration of 0.1 mg/mL to 20 mg/mL.
18: The sustained release formulation of claim 12 , wherein the isotonic agent is included in a concentration of 1 mg/mL to 100 mg/mL.
19: The sustained release formulation of claim 2 , which comprises 50 mg to 1200 mg of the active ingredient per a container.
20: The sustained release formulation of claim 2 , which passes through a needle of 18 to 23 gauges.
21: The sustained release formulation of claim 2 , which is a depot formulation.
22: A method for treating psychiatric disease, comprising:
administering the sustained release formulation of claim 2 .
23: The method of claim 22 , wherein the psychiatric disease is schizophrenia.
24: The method of claim 22 , wherein the psychiatric disease is bipolar disorder.
25: The method of claim 22 , wherein the psychiatric disease is depression.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/128,597 US20190010149A1 (en) | 2010-10-18 | 2018-09-12 | Sustained-release formulation for injection |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39406910P | 2010-10-18 | 2010-10-18 | |
US13/276,039 US9469630B2 (en) | 2010-10-18 | 2011-10-18 | Sustained-release formulation for injection |
US15/043,235 US20160158228A1 (en) | 2010-10-18 | 2016-02-12 | Sustained-release formulation for injection |
US16/128,597 US20190010149A1 (en) | 2010-10-18 | 2018-09-12 | Sustained-release formulation for injection |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/043,235 Division US20160158228A1 (en) | 2010-10-18 | 2016-02-12 | Sustained-release formulation for injection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190010149A1 true US20190010149A1 (en) | 2019-01-10 |
Family
ID=45933169
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/276,039 Expired - Fee Related US9469630B2 (en) | 2010-10-18 | 2011-10-18 | Sustained-release formulation for injection |
US15/043,235 Abandoned US20160158228A1 (en) | 2010-10-18 | 2016-02-12 | Sustained-release formulation for injection |
US16/128,597 Abandoned US20190010149A1 (en) | 2010-10-18 | 2018-09-12 | Sustained-release formulation for injection |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/276,039 Expired - Fee Related US9469630B2 (en) | 2010-10-18 | 2011-10-18 | Sustained-release formulation for injection |
US15/043,235 Abandoned US20160158228A1 (en) | 2010-10-18 | 2016-02-12 | Sustained-release formulation for injection |
Country Status (7)
Country | Link |
---|---|
US (3) | US9469630B2 (en) |
EP (1) | EP2629775A4 (en) |
JP (4) | JP5893616B2 (en) |
KR (1) | KR101936968B1 (en) |
CN (3) | CN103249416B (en) |
CA (1) | CA2814840C (en) |
WO (1) | WO2012053654A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478131A (en) * | 2019-08-05 | 2019-11-22 | 思必康(厦门)新材料有限公司 | A kind of pH responds the application of gauze of discoloration and preparation method thereof with the gauze |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR090775A1 (en) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | INJECTABLE PREPARATION |
JOP20200109A1 (en) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
WO2014084921A1 (en) * | 2012-11-27 | 2014-06-05 | Rose Stuart | Pharmaceutical manufacturing method and compositions |
US20160022725A1 (en) * | 2013-03-15 | 2016-01-28 | Epizyme, Inc. | Injectable formulations for treating cancer |
TW201609145A (en) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | Injectable agent and depot formation method |
WO2016044649A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
KR101792414B1 (en) * | 2016-05-19 | 2017-11-01 | 삼성전기주식회사 | Thin film capacitor and manufacturing mathod of the same |
CN105963253A (en) * | 2016-06-19 | 2016-09-28 | 朱武欣 | Rotigotine long-acting waterborne suspension type injection |
WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
CN109640996A (en) * | 2016-08-31 | 2019-04-16 | 大日本住友制药株式会社 | Aqueous suspension type preparation |
US10252229B2 (en) * | 2017-06-30 | 2019-04-09 | Snowie LLC | System comprising a pump attached to a tank casing for mixing a fluid |
SG11202008233WA (en) * | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation with controlled dissolution |
SG11202008204QA (en) * | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation |
JP7214103B2 (en) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | game machine |
JP7214100B2 (en) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | game machine |
JP7214102B2 (en) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | game machine |
WO2020179925A1 (en) * | 2019-03-07 | 2020-09-10 | 大日本住友製薬株式会社 | Aqueous suspension-type pharmaceutical preparation with controlled particle size |
US11814397B2 (en) * | 2020-03-27 | 2023-11-14 | Boston Scientific Scimed, Inc. | Methods for crystallization of drugs |
EP4196106A1 (en) * | 2020-08-11 | 2023-06-21 | Auxilla Pharmaceuticals and Research LLP | A non-aqueous suspension of anticancer agent |
AU2022226584A1 (en) | 2021-02-24 | 2023-08-17 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
WO2022206447A1 (en) | 2021-03-31 | 2022-10-06 | 四川科伦药物研究院有限公司 | Injectable lurasidone suspension and preparation method therefor |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2800953B2 (en) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | New imide derivatives |
TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
US6169084B1 (en) | 1997-09-30 | 2001-01-02 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
FI105074B (en) | 1997-12-31 | 2000-06-15 | Leiras Oy | Process for the preparation of a pharmaceutical formulation |
ID29574A (en) | 1998-09-30 | 2001-09-06 | Lilly Co Eli | 2-METHYL-TIENO-BENZODIAZEPIN FORMULATION |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
WO2002078673A1 (en) | 2001-03-29 | 2002-10-10 | Takeda Chemical Industries, Ltd. | Process for producing fine granulate drug |
JP4175800B2 (en) * | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | Method for producing imide derivative |
DE10218110A1 (en) | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Process for the preparation of crystals of pharmaceutical excipients, crystals available thereafter and their use in pharmaceutical formulations |
GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
AU2004259305B2 (en) | 2003-07-29 | 2009-06-04 | Sumitomo Pharma Co., Ltd. | Process for producing imide compound |
US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
WO2005041937A2 (en) | 2003-10-23 | 2005-05-12 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
EP2623095A1 (en) | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
SI1838716T1 (en) | 2005-01-05 | 2011-10-28 | Lilly Co Eli | Olanzapine pamoate dihydrate |
JP2008538751A (en) | 2005-04-13 | 2008-11-06 | ファイザー・プロダクツ・インク | Injectable depot formulations and methods for sustained release of nanoparticle compositions |
AU2006250340C1 (en) | 2005-05-26 | 2014-06-12 | Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
JP4866349B2 (en) * | 2005-06-13 | 2012-02-01 | 大日本住友製薬株式会社 | Solubilized preparation |
JP2009508859A (en) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate aripiprazole formulation |
KR20080110807A (en) | 2006-03-14 | 2008-12-19 | 머크 앤드 캄파니 인코포레이티드 | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use |
BRPI0820745A2 (en) | 2007-12-13 | 2015-06-16 | Novartis Ag | Organic compounds |
-
2011
- 2011-10-18 WO PCT/JP2011/074375 patent/WO2012053654A1/en active Application Filing
- 2011-10-18 KR KR1020137011618A patent/KR101936968B1/en active IP Right Grant
- 2011-10-18 JP JP2013517506A patent/JP5893616B2/en not_active Expired - Fee Related
- 2011-10-18 US US13/276,039 patent/US9469630B2/en not_active Expired - Fee Related
- 2011-10-18 CN CN201180060225.0A patent/CN103249416B/en not_active Expired - Fee Related
- 2011-10-18 CN CN201710826877.XA patent/CN107625728A/en active Pending
- 2011-10-18 EP EP11834492.8A patent/EP2629775A4/en not_active Withdrawn
- 2011-10-18 CA CA2814840A patent/CA2814840C/en not_active Expired - Fee Related
- 2011-10-18 CN CN201710826880.1A patent/CN107595771A/en active Pending
-
2016
- 2016-02-12 US US15/043,235 patent/US20160158228A1/en not_active Abandoned
- 2016-02-24 JP JP2016033019A patent/JP6173502B2/en not_active Expired - Fee Related
-
2017
- 2017-07-04 JP JP2017131059A patent/JP6410889B2/en not_active Expired - Fee Related
-
2018
- 2018-09-12 US US16/128,597 patent/US20190010149A1/en not_active Abandoned
- 2018-09-25 JP JP2018179030A patent/JP2019006822A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478131A (en) * | 2019-08-05 | 2019-11-22 | 思必康(厦门)新材料有限公司 | A kind of pH responds the application of gauze of discoloration and preparation method thereof with the gauze |
Also Published As
Publication number | Publication date |
---|---|
US20160158228A1 (en) | 2016-06-09 |
EP2629775A4 (en) | 2014-06-11 |
JP2019006822A (en) | 2019-01-17 |
JP5893616B2 (en) | 2016-03-23 |
US20120091022A1 (en) | 2012-04-19 |
EP2629775A1 (en) | 2013-08-28 |
CN107625728A (en) | 2018-01-26 |
CN103249416B (en) | 2019-06-04 |
JP6410889B2 (en) | 2018-10-24 |
CA2814840C (en) | 2018-08-28 |
JP2013543481A (en) | 2013-12-05 |
CN103249416A (en) | 2013-08-14 |
KR101936968B1 (en) | 2019-01-09 |
JP2017206543A (en) | 2017-11-24 |
CN107595771A (en) | 2018-01-19 |
CA2814840A1 (en) | 2012-04-26 |
JP2016128503A (en) | 2016-07-14 |
US9469630B2 (en) | 2016-10-18 |
WO2012053654A1 (en) | 2012-04-26 |
JP6173502B2 (en) | 2017-08-02 |
KR20130139978A (en) | 2013-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190010149A1 (en) | Sustained-release formulation for injection | |
US9096547B2 (en) | Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide | |
IL265260A (en) | Pharmaceutical composition | |
JP2013543481A5 (en) | ||
JP2007532619A (en) | Liquid containing suspended glass particles | |
EP2506878A2 (en) | Process for preparing pharmaceutical ophthalmic compositions | |
KR102004341B1 (en) | Pharmaceutical pemetrexed solution | |
CN110464846A (en) | A kind of Meloxicam composition, preparation and the preparation method and application thereof | |
CN106137985A (en) | A kind of stable Palmic acid 9-hydroxy-risperidone durative action preparation | |
US10463674B2 (en) | Process for manufacturing sterile ophthalmic pharmaceutical suspensions | |
US20240197623A1 (en) | Silica-based formulations of therapeutic oliogpeptides and peptidomimetics | |
WO2019213286A1 (en) | Extended release suspension formulation of lurasidone | |
WO2024071348A1 (en) | Sterilized heterocyclidene-acetamide-derivative-containing suspension | |
CN117425486A (en) | Silica-based formulations of therapeutic oligopeptides and peptidomimetics | |
WO2011016435A1 (en) | Method for producing freeze-dried composition containing polylactic acid particles | |
JP2019163227A (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |